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1. Introduction 
1.1. Comparative aspects on canine and human neoplasias 
Cancer is a major public health problem worldwide. In 2008, 12.7 million new cases 
of cancer were diagnosed and 7.6 million people died from the disease. This number 
represents 13 % of all deaths around the world. Of there, lung, stomach, liver, colon, 
breast and prostate cancer cause the most cancer deaths each year [1]. A prediction 
of the World Health Organization (WHO) states that deaths from cancer worldwide 
are continuously increasing with an estimated number of 13.1 million deaths in 2030. 
More than 30 % of cancer deaths (39 % for men and 19 % for women) are 
considered to be caused by exposure to influential risk factors (e.g. smoking, bad 
dietary, lack of physical activity, excessive alcohol consumption) and can be avoided 
by changing the lifestyle [1, 2].  
Extensive research in human cancer medicine is carried out to decipher the 
processes involved in the development and metastasis of tumours. To establish and 
improve anticancer therapies, numerous animal models for different human cancer 
types are available as comparative living systems recapitulating the natural history of 
cancers and their response to therapeutic agents [3, 4]. Genetically engineered 
(transgenic and knockout) or immunocompromised murine xenografts with implanted 
tumour cell lines or tissues are most widely-used as in vivo models providing insight 
in the biology and genetics of human cancers. Mouse models have been extremely 
useful, but significant limitations are the specific differences between the species and 
the lack of spontaneous tumour development [3, 5].  
Moreover, some physiopathologic characteristics caused by naturally occurring 
tumours cannot be resembled that closely by induced xenografts tumours. Thus, 
animal models in which cancers are spontaneously occurring, have gained 
considerable interest in human cancer research.  
The dog is one of the companion animals being considered as an important model 
system. Canine neoplasias are developing spontaneously in the context of an intact 
immune system within a syngeneic host and tumour microenvironment enabling new 
prospects for cancer immunotherapy [5-7]. With their human counterparts, the 
spontaneous tumours in dogs have been described to share many epidemiologic, 
histopathologic and biologic features (e.g. tumour progression, metastatic pattern) 
that are difficult to reproduce in other animal model systems [5, 8, 9]. In dogs, 
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recurrences as well as similar response rates to conventional chemotherapy 
protocols are also observed as present in humans [5, 9, 10].  
Similar to humans, in dogs cancer is one of the leading natural cause of death. 
Regardless of age, one of four dogs is reported to die of cancer, while for older 
individuals with an age of 10 years the death rate with one of two is much higher [11]. 
Dogs develop tumours at similar sites as humans, but twice as frequently [8]. 
Therefore, the cancer development in dogs can be observed at an accelerated pace 
and the response to novel cancer therapeutic options can be tested faster to success 
with transferable results for humans [8]. Dogs share also many environmental risk 
factors as exposure to carcinogenic substances (including passive tobacco smoking) 
and effects induced by living conditions such as bad nutrition with their human 
owners [12]. Furthermore, the dog receives very good medical health care which in 
turn leads to a detailed surveillance of cancer development, progression and success 
of tumour therapy [13, 14]. The superior health care provides also the benefit to 
obtain adequate tumour samples, non-neoplastic tissue biopsies as well as blood or 
bone marrow during medical check-up or surgery [10].  
Several distinct canine cancers such as osteosarcoma, mammary carcinoma, oral 
melanoma, oral squamous cell carcinoma, nasal tumours, lung carcinoma, soft tissue 
sarcomas, and malignant non-Hodgkin's lymphoma (NHL) are known to have the 
same naturally occurring tumour mechanisms as their human counterparts making 
them relevant for comparative therapeutic studies [8, 10]. A recent review by 
Marconato et al. in 2012 underlines the similarities between canine and human NHL 
including the clinical, clinical-pathological and histological correspondence as well as 
the genomic instability [15-17]. With the analysis of chromosomal copy number 
aberrations in dogs by comparative genomic hybridisation (CGH), the detection of 
genomic imbalances was possible in canine NHL. Compared to human CGH 
analyses, recurrent chromosome aberrations in canine NHL were also present, but 
lower than in human NHL showing less copy number aberrations [15, 17, 18]. 
Notable differences were also found e.g. in the distribution of subtypes of T-cell and 
B-cell lymphomas in the human and canine population. In detail, in dogs T-zone and 
nodal marginal zone lymphomas are common and rare in humans. In contrast, 
Burkitt-like and follicular lymphomas are infrequent in dogs and occurring more often 
in people [15, 19].  
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The incidence rates for certain tumour types like e.g. canine osteosarcoma and 
non-Hodgkin’s lymphoma are reported to be significantly higher than those observed 
for humans increasing the potential of serving as appropriate model for the human 
malignancy [10].  
The release of the entire canine genome sequence in 2005 revealed a strong genetic 
similarity to the human genome [20]. It turned out that many genes are present in a 
preserved order with up to 95 % synteny between dog and man concerning different 
chromosome segments [21]. This information offers the opportunity to investigate the 
development and biologic behaviour of tumours and to identify cancer-associated 
target genes comparatively in human and dog patients, which provides reciprocal 
benefit for both species [13, 22]. The characterisation of the molecular structure and 
function of the target genes and the respective proteins is a prerequisite to elucidate 
their involvement in pathogenic processes. With the identification of molecular targets, 
the establishment of gene-therapeutic strategies or diagnostic approaches is strongly 
facilitated. The development of advanced technologies and highly validated research 
methodologies enabled the identification of new genes which are also related to 
cancer [23]. 
Two targets which are generally known to contribute to carcinogenesis and other 
pathogenic processes in humans are high-mobility group box 1 (HMGB1) and the 
receptor for advanced glycation end products (RAGE) as one of its receptors. The 
genetic structure of the canine homologues of these genes was characterised by 
Murua Escobar et al. in 2003 for HMGB1 [24] and in 2006 for RAGE [25] creating a 
basis for comparative oncology research in dogs.  
Based on these data, during this thesis further basic research on the canine HMGB1 
and RAGE was carried out. Furthermore, this thesis covers research that has been 
conducted in other areas than structure, function and expression of canine cancer-
related genes, which can also contribute valuable findings to the establishment of 
preclinical therapies against cancer.  
1.2. HMGB1 - nuclear and extracellular functions 
The high-mobility group box protein 1 (also designated as HMG-1 or amphoterin) is a 
ubiquitously expressed non-histone nuclear protein with double function belonging to 
the HMG-protein-superfamily [26, 27]. HMGB1 is highly conserved amongst almost 
all eukaryotic cells. The human protein is composed of 215 amino acids (aa) and has 
a size of ~30 kDa. The comparison of various species showed that the human 
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HMGB1 protein sequence is 100 % identical to canine HMGB1 [24] and 99 % 
identical to mouse, rat, bovine, and porcine HMGB1 [28-31]. Due to the 100 % 
identity between human and dog HMGB1 is an interesting protein in terms of 
comparative oncology. The protein structure of HMGB1 is composed of two 
homologous DNA binding domains (boxes A and B) and a highly negatively charged, 
acidic C-terminal domain of about 30 asparagine and glutamine residues [32, 33]. 
The A and B boxes are consisting each of three α-helices which are stabilized by a 
hydrophobic core and arranged in an L-shape [34].  
Nuclear HMGB1 plays a role as DNA-binding protein to sustain nucleosome structure 
and acts as architectural transcription factor [35]. HMGB1 binds structure-specific to 
the minor groove of the DNA and is able to induce transient bends or kinks into parts 
of linear DNA thereby directly influencing the attachment of other transcription factors 
to their target sequence in a positive or negative way [36-38]. In this function, 
HMGB1 is reported to modulate the activity of a number of transcription factors 
including retinoblastoma protein (pRb) [39], members of the Rel/NFκB family [40], the 
tumour suppressor p53 [41] and its homologue p73 [42] and steroid hormone 
receptors [43-45].  
HMGB1 has also the ability to bind to damaged DNA. The protein is in this role 
reported to be a key player enhancing nucleotide excision repair and chromatin 
modification after DNA damage [46, 47]. In terms of cancer, it was demonstrated that 
HMGB1 has also a higher affinity to the anticancer drug cisplatin forming complexes 
with DNA [48-50]. HMGB1 inhibits the repair of these cisplatin-DNA adducts leading 
to an enhanced sensitivity of cells to cisplatin [51-53]. The generation of HMGB1 
knockout mice dying 24 h after birth from hypoglycemia and an improper regulation of 
the glucocorticoid receptor revealed that HMGB1 is indispensable for live [54].  
Apart from its intranuclear role, HMGB1 can be localized in the extracellular matrix 
exerting function as a proinflammatory cytokine which was firstly identified in 1999 by 
Wang et al. [55]. The effects of HMGB1 in its cytokine function are mediated by its 
functional domains. The B box mediates proinflammatory activity recapitulating the 
capacity of the full-length protein [56-59] while the A box was shown to act as an 
antagonist [56, 60-62].  
Two main ways of HMGB1 release are known at present: passive and active release. 
In necrotic or damaged cells dying inadvertently in a traumatic way, HMGB1 is 
passively released and takes part in the mediation of inflammation, immune system 
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activation, tissue repair, induces the migration and activation of dendritic cells (DCs) 
and attracts leukocytes to the inflammated areas [57, 63-65]. HMGB1 thereby 
functions as an indicator forwarding the dimension of tissue injury to the immune 
system [66]. In contrast to necrotic cells, cells undergoing apoptosis were initially 
described to be HMGB1 non-secreting as the protein stays tightly associated to the 
chromatin [63]. Some later reports revealed that apoptotic cells can also release 
HMGB1, and this extracellular HMGB1 is tolerated by the immune system instead of 
mediating proinflammatory effects [67, 68].  
It was shown that the caspase-dependent reversible oxidation of the cysteine aa 
residue 106 (Cys106) in the presence of reactive oxygen free radicals play the 
central role in the modulation of HMGB1 activity [69]. Cys106 is localised within the 
cytokine-inducing, inflammation mediating B box [56, 62] and is essential for 
interaction of HMGB1 with Toll-Like Receptor (TLR) 4 [70]. The fully reduced form of 
HMGB1 has chemoattractant activity, while HMGB1 with cytokine activity contains a 
disulfide bridge between the Cys23 and Cys45 and a reduced Cys106 [71]. This 
cysteine oxidation mechanism for HMGB1 activity regulation is not only existent in 
apoptotic cells but also hypothesised to control the proinflammatory function of 
HMGB1 in vivo, where a largely oxidative extracellular environment is present during 
inflammatory processes [71].  
Besides passive release, HMGB1 actively can be released from activated immune 
cells including monocytes, macrophages, dendritic cells, pituicytes, natural killer cells, 
endothelial cells and platelets [72-78]. Those cells release HMGB1 as a response to 
exogenous bacterial products (e.g. LPS or CpG-DNA) [55, 79] or endogenous host 
stimuli causing cellular responses like inflammation, sepsis, development of acute 
lung injury as well as stimulation of cytokine expression and secretion [55, 72, 75, 80]. 
Monocytes/macrophages were stimulated in vitro with LPS, TNF-α or IL-1β and found 
to release HMGB1 in a time-dependent manner delayed by several hours in 
comparison to other proinflammatory cytokines [55, 72, 80]. In vivo increased serum 
levels of HMGB1 could be detected in BALB/c mice beginning approximately 8 h after 
onset of endotoxemia as well as in a model of sepsis and reaching highest levels 
after 12-20 h in comparison to other ‘early’ proinflammatory cytokines [55, 62, 81]. As 
well cells not belonging to the immune system such as adenocarcinoma derived 
tumour cell lines and mouse intestinal epithelial cells were shown to be capable to 
secrete HMGB1 [82-85]. Before active secretion, HMGB1 was reported to undergo 
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extensive acetylation of specific lysine residues [86]. The protein accumulates in the 
cytoplasm as the re-entry to the nucleus is blocked by the modifications [86] and is 
released via non-classical pathway by exocytosis of secretory lysosomes [87]. 
HMGB1 plays a complex role in the development and progression of cancer. The 
gene is found to be overexpressed in some types of cancers like human 
gastrointestinal stromal tumours [88], and gastrointestinal adenocarcinomas [89], 
human malignant melanomas [90], breast [91, 92], and prostate cancer [93], canine 
osteosarcomas and fibrosarcomas [94], in human leukaemia cell lines [95], and 
human and canine Non-Hodgkin lymphoma [96, 97]. Accordingly, extracellular 
HMGB1 is supposed to play a key role in the promotion of tumour growth, because it 
is accredited to cause angiogenic effects by increasing the expression of 
angiogenesis-related cytokines and growth factors [98, 99].  
1.3. Receptors of HMGB1 
Once released, the extracellular effect is mediated by interaction with at least five 
different membrane receptors as the receptor for advanced glycation end products 
(RAGE) [100], the Toll-like receptors (TLR)-2, -4 and -9 [58, 59, 101, 102], triggering 
receptor expressed on myeloid cells-1 (TREM-1) [103], and the glycosyl 
phosphatidylinositol-anchored CD24 membrane protein [71, 104, 105]. RAGE was 
the first identified receptor for HMGB1, but it was hypothesised that interaction of 
HMGB1 solely with RAGE could not lead to all the effects provoked by HMGB1. Later 
on, signalling via alternative receptors like the above-mentioned TLRs was 
discovered.  
HMGB1 interacts with TLR-2 and TLR-4 via an epitope in its B box. This enables 
cells of the innate immune system to respond to various exogenous and endogenous 
stimuli [57-59] leading to cell activation (e.g. macrophages) and NFκB-dependent 
expression of proinflammatory cytokines [59, 101, 106].  
TLR-9 is essential for recognition of unmethylated microbial CpG-DNA inducing 
macrophages, monocytes and DCs to secret proinflammatory cytokines leading to 
the elimination of microbial pathogens by activation of plasmacytoid DCs and B-cells 
[79, 107-110]. Synthetic short single stranded unmethylated oligonucleotides with a 
CpG motif (CpG-ODN) are also interacting in the same way as microbial CpG-DNA 
with TLR-9, thus being attractive for therapeutic vaccine strategies aiming at the 
stimulation of immune responses in the focus of e.g. infectious diseases or cancer 
[79, 111-113]. HMGB1 itself was also identified as a CpG-ODN binding protein [79, 
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102]. Triggered by CpG-ODN, HMGB1 is able to enhance TLR9-dependent cytokine 
responses inside the cell, whereas extracellular HMGB1 helps to accelerate the 
formation of CpG-DNA/TLR-9 complexes [79]. Another study published in the same 
year indicated that the TLR-9 dependent activation by DNA containing immune 
complexes is mediated by HMGB1 and RAGE. These findings demonstrate a 
previously unknown close relationship between those three proteins [102, 114].  
Physiological and pathophysiological outcomes of HMGB1 in interaction with the cell 
surface have been mostly associated to RAGE signalling [115]. As described 
previously, RAGE was the first receptor being identified to interact with HMGB1 [100]. 
Therefore, the focus in this thesis is set on RAGE in reference to receptors 
interacting with HMGB1.  
1.4. RAGE 
RAGE is a member of the immunoglobulin superfamily of cell surface molecules 
which was initially identified to act as a receptor for advanced glycation end products 
(AGEs) [116, 117]. Later, it was shown that RAGE interacts, besides the AGEs, with 
multiple ligands including HMGB1, members of the calcium-binding S100 protein 
family, amyloid-β and macrophage-1 antigen [100, 118-120]. Depending on the 
ligands, RAGE has been described to be involved in a variety of human immune 
system dysfunctions and inflammatory disorders [119, 121-123], Alzheimer’s disease 
[118, 124, 125, reviewed also in 126], in diabetes and its associated disorders such 
as atherosclerosis [122, 127-130], impaired wound healing [131], and various 
cancers [reviewed in 132].  
RAGE is expressed in numerous cells like endothelial cells, vascular smooth muscle 
cells, neurons, macrophages / monocytes [133]. High expression levels of RAGE 
were detected in lung tissue [134], atherosclerotic plaques [128, 135] and in the brain 
of rats during embryonic development while becoming lower in adult tissues [100]. As 
well large amounts of RAGE are observed in pathologic states like those described 
above.  
The gene encoding the human RAGE consists of 11 exons / introns. The protein is 
composed of three extracellular immunoglobulin-like domains (V, C1 and C2), a 
single transmembrane domain (TM), and a short highly charged C-terminal cytosolic 
domain essential for cell signalling [116, 122]. The V-domain was identified as the 
ligand-binding domain. The interaction of HMGB1 with RAGE is mediated by a region 
consisting partly of the B box and the acidic C-terminal domain of the molecule [60]. 
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Characterisation of the canine RAGE revealed a total identity of 77.6 % to the human 
counterpart [25].  
Besides the full-length RAGE several naturally occurring splice variants were 
detected in humans characterised by C-terminal or N-terminal truncations lacking the 
TM and cytosolic tail or the ED domain respectively [136-143, reviewed also in 144]. 
The C-terminal truncated forms are released into the extracellular compartment 
interacting there as a soluble binding partners for RAGE ligands, but the exact 
biological role of this soluble variants remains still to be elucidated. Those soluble 
RAGE variants can exist in different isoforms which include RAGEv1, formed through 
alternative splicing, and esRAGE, generated by shedding of the extracellular domain 
from transmembrane RAGE [145, 146, reviewed also in 147].  
In general, the diverse variants of RAGE are discussed to act as mechanisms for 
receptor regulation by competitive inhibition [reviewed in 148, 149]. An imbalance 
between the full-length RAGE and its soluble variants was reported to be involved 
inter alia in several clinical settings which were previously accredited to the full-length 
receptor including immune-mediated diseases (e.g. rheumatoid arthritis) [121, 150], 
Alzheimer’s disease [125, 126, 151], diabetes mellitus type 1 and 2 [152-158], 
atherosclerosis [127, 159-161], neurodegenerative diseases as for example multiple 
sclerosis or amyotrophic lateral sclerosis (ALS) [162-164], and cancer [reviewed in 
132, 165]. The analysis of RAGE splicing variants expressed in canines will be 
discussed later within this thesis.  
1.5. HMGB1 signalling via RAGE  
HMGB1 in its role as a ligand of RAGE is supposed to be involved in growth and 
actin mobilisation in normal cells [166]. Regarding tumour biology the RAGE-HMGB1 
ligand-receptor complex regulates proliferation, migration and metastasis of tumour 
cells by activation of signal transduction pathways like p21ras, mitogen activated 
protein (MAP) kinases, p38, JNK (c-Jun NH2-terminal kinase), cdc42/rac and p44/p42, 
which in turn leads to activation of the transcription factor nuclear factor kappa B 
(NFκB) [61, 167-171].  
In vivo and in vitro experiments by Taguchi et al. published in the year 2000 
demonstrated that the blockade of the RAGE/HMGB1 complex significantly 
suppressed local tumour growh and metastasis by application of a soluble RAGE 
variant (sRAGE) and anti-RAGE or anti-HMGB1 antibodies [170]. These findings 
provided a wide range of potential therapeutic options targeting at the blockade of 
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RAGE/HMGB1 complex in terms of cancer as well as inflammatory processes. Since 
then, the application of sRAGE in vitro and in vivo in several animal models targeting 
at the treatment of different human diseases was effectively realised [121, 131, 172-
175]. Nevertheless, the sRAGE blocking strategy needs to be considered carefully, 
because it has been shown that sRAGE seems to have more effects than simply 
blocking the function of full-length RAGE as cell surface receptor [176, 177]. Besides 
blocking of the RAGE/HMGB1 complex with sRAGE, alternative strategies for 
therapeutic HMGB1 inhibition have been evaluated so far. An inhibitory synthetic 
RAGE-binding C-terminal HMGB1 motif was shown to prevent the metastasis of 
melanoma cells in vivo by blocking the RAGE/HMGB1 complex [60]. Further, several 
experimental methods for therapeutic HMGB1 inhibition are focussing on the 
neutralisation of HMGB1 using anti-HMGB1 antibodies or on the administration of the 
inhibitory HMGB1 A box to block the ligand-receptor interaction [62, reviewed in 178]. 
Neutralising anti-HMGB1 antibodies were shown to inhibit the release of 
inflammatory cytokines, but a prevention of HMGB1 secretion cannot be 
accomplished with this strategy [55, 62, 176, 179].  
A deregulated expression of both, HMGB1 and RAGE, was found in various types of 
human neoplasias including breast, colon, prostate, pancreatic, lung and 
oesophageal cancers and glioma being strongly associated with the aggressive 
potential and metastasis of the tumour cells [reviewed in 165, 180]. In dogs, only few 
analyses targeting at the expression of HMGB1 and RAGE have been performed so 
far [24, 25, 94].  
As previously mentioned, lymphoma is a commonly occurring spontaneous neoplasia 
in dogs similar to human non-Hodgkin’s lymphoma. Data concerning expression of 
HMGB1 and RAGE in lymphomas are rare [96, 97, 181] lacking the simultaneous 
analysis of both genes. During this thesis, the expression patterns of HMGB1 and 
RAGE were analysed in a set of canine lymphomas and control samples. Due to the 
previously described high similarity of the human and canine RAGE and HMGB1 
proteins especially in their interacting domains, those targets could serve for future 
development and evaluation of tumour therapeutic approaches providing benefit for 
humans as well as dogs.  
In contrast to the proinflammatory and tumour progressing functions of HMGB1, there 
is much evidence that HMGB1 induces also beneficial effects. HMGB1 can mediate 
the activation of immune responses to confine infections, and to promote tissue 
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remodelling and repair [182-184]. In addition, HMGB1 is discussed to have 
precondition ability. A low level of HMGB1 was shown, by binding to TLR-4, to act as 
a stressful stimulus reducing injury significantly in various disease states [185, 186]. It 
seems that the HMGB1 mediated effects are varying from beneficial to pathological in 
a concentration-dependent manner [182, 184]. From the inflammatory, immune 
system activating potential of HMGB1 benefits can be drawn to develop new 
therapeutic strategies aiming at cancer immunotherapy. In combination with RAGE, 
HMGB1 was shown to be essential for DC activation, maturation and chemotactic 
migration [187-189]. DCs are the most professional antigen presenting cells (APC) 
playing a major role in the initiation and regulation of immune responses [190]. 
Blocking the HMGB1-RAGE complex was reported to inhibit the maturation of DCs 
[187, 191, 192]. The DC migration towards peripheral lymph nodes was also shown 
to be mediated by RAGE in vivo [189]. In turn, activated DCs themselves also are 
able to secrete HMGB1 in response to inflammatory stimuli resulting in an ‘autocrine-
loop’ playing a significant role in the proliferation, survival, and functional polarisation 
of naïve T-cells [65, 192]. Recently it has been also shown that stimulation with 
recombinant HMGB1 has a proliferative effect on canine peripheral blood 
mononuclear cells (PBMC) [193].  
1.6. Cancer immunotherapy  
Cell-based vaccination therapy with tumour antigen-loaded DCs has become of 
special interest as promising immunotherapeutic approach for treatment of cancer. 
Cancer immunotherapy is based on the assumption, that cancer cells have the ability 
to evade the host immune system, in part by expressing immunosuppressive 
cytokines, which prevent the activation of tumour reactive T-cells [194]. An 
immunization strategy is to stimulate the immune system for the detection of cancer 
cells and to induce an immune response by DC application. DCs can be easily 
generated ex vivo by differentiation from hematopoietic stem cells, PBMCs, or 
monocytes under cytokine-stimulating conditions [195].  
DC vaccines were used successfully for the first time in patients with non-Hodgkin’s 
lymphoma who had failed conventional chemotherapy [196]. In this clinical trial, 
autologous DCs were pulsed ex vivo with immunoglobulin idiotype obtained from the 
patient’s tumour and re-injected to stimulate host anti-tumour immunity by priming DC 
mediated T-cell responses [196].  
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Up to now, the current approaches are still challenging because those DC vaccines 
in some cases show less immunogenic potential, e.g. by the DC maturation state 
influencing the migration activity [197, 198]. To improve the therapeutic utility of DC 
vaccines in terms of antigen presentation, co-stimulation and cytokine production, 
several strategies are followed. Those strategies are using DNA, mRNA, viruses to 
genetically modify DCs for endogenous expression and processing of 
tumour-associated antigens or immune response factors or to express cytokines, 
chemokines, and other co-stimulatory molecules [199, 200].  
One approach, aiming at the development of an effective DC vaccine strategy for 
enhancement host anti-tumour responses is addressed by an interdisciplinary 
collaborate research centre Transregio 37 (CRC / TR37). Parts of this thesis were 
conducted to support the development of this immunotherapeutic approach. 
Within the CRC / TR37, the establishment of a genetically engineered recombinant 
HMGB1-secreting DC vaccine with enhanced immunostimulatory potential in the dog 
as model organism is aspired. In detail, one goal of this project is to achieve a highly 
efficient method for transfection of canine haematopoietic stem cells (HSC) with 
HMGB1 expression plasmids using the novel femtosecond (fs)-laser technology. In 
addition, the expansion and differentiation of the modified stem cells to cHMGB1 
expressing DC are examined. The application of the engineered DCs as a vaccine in 
dogs and the characterisation of the migration behaviour of those DCs in vivo are 
also aimed in this project.  
To follow therapeutic approaches as described in the CRC / TR37 targeting at in vivo 
application of genetically ‘engineered’ stem or primary cells, high transfection 
efficiencies are necessary. To introduce nucleic acids or other molecules deliberately 
into eukaryotic cells, transfection is an essential biological key technique used in 
areas of basic research and consequently for implementation of gene-therapeutic 
approaches. Standard non-viral transfection, e.g. via chemical-based 
liposome-mediated or cationic methods and the physical method of electroporation, 
have been shown to be sufficient for fast proliferating cells, but inadequate for 
transfection of stem cells or primary cells as to unsatisfactory efficiencies or cell toxic 
side effects [201-204]. Stem cells like e.g. HSCs are regarded to be notoriously 
difficult to transfect [205]. Transduction with viral vectors as an alternative to the 
non-viral transfection also revealed limitations and pitfalls in terms of biosafety, 
inflammatory potential and efficiency [204, 206]. Against the background of the 
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described limitations, the difficult isolation and availability of limited stem cell 
populations, novel strategies besides the conventional transfection methods are 
needed.  
The opto-perforation of the cell membrane using fs-laser pulses is a new, very 
versatile method for cell-type independent transfection selectively targeting single 
cells [207, 208]. In contrast to the commonly used electroporation perforating the 
whole cell membrane, fs-laser pulses are focused on a small region of the membrane. 
The shortness of the laser pulse causes almost no heating due to the fact that the 
applied pulse duration is shorter than the duration of thermal conveyance 
(picoseconds to nanoseconds). Thus, thermal shock and mechanical damage can be 
neglected in this context [207, 209, 210]. The application of fs-laser pulses leads to a 
precise and gentle opening of a transient pore in membrane with less than one 
micrometer in diameter affecting only a small volume of some femtoliters allowing the 
diffusion of extracellular nucleic acids or other molecules into the cell [209].  
Another novel approach for achieving enhanced transfection efficiencies is the 
application of nanoparticles for introduction of nucleic acids and other biomolecules 
into cells. Especially gold nanoparticles (AuNP) are currently focussed in research 
due to their outstanding characteristics in terms of biocompatibility, chemical stability, 
surface functionalisation properties, electrodensity and affinity to biomolecules such 
as DNA when those AuNPs have an electrical charge [211, 212]. AuNP can be 
generated by various methods, predominantly relying on chemical reactions or gas 
pyrolysis [213]. Those methods are bearing the risk of impurities emerging during 
generation or formation of agglomerates [213]. A new technique generating 
stabilizer-free AuNP by pulsed laser ablation in liquids (PLAL) has been shown to be 
a powerful tool to obtain highly pure colloidal particles without any chemical surface 
modifications making those particles interesting for biomedical applications [214, 215]. 
Those positively charged PLAL-AuNPs were recently shown to easily adsorb 
unmodified, negatively charged DNA oligonucleotides providing an interesting tool for 
improvement of DNA transfection of difficult cells [216].  
After successful transfection, a next step to be performed within the CRC / TR37 is 
the expansion and differentiation of the genetically modified stem cells to 
recombinant HMGB1 expressing DCs. For the characterisation of the trafficking 
patterns of such administrated DC vaccines, suitable non-invasive, non-toxic in vivo 
imaging methods are needed to monitor the fate and migration of transplanted cells. 
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One strategy for non-invasive in vivo imaging of applied DCs is the tracking via DC-
specific fluorophore-coupled antibodies. In humans, DC specific antibodies directed 
against CD40, CD80, and CD83 are commonly used for characterisation of the DC 
maturation state [217]. Those antibodies might also be used for quantification, 
separation and specific immunological or direct in vivo visualisation. Up to now, the 
availability of antibodies binding specifically to canine DCs is severely limited, making 
the detection of DCs in canine tissues challenging [217].  
Another powerful option for cellular in vivo tracking appears to be the magnetic 
resonance imaging (MRI) technique as promising clinically transferable tool, with high 
spatial resolution, a long effective imaging window, and fine signal intensity [218-220]. 
In order to detect transplanted cells by MRI, the cells must be labelled with an 
effective contrast agent. Due to their low toxicity and high biocompatibility, different 
types of superparamagnetic iron oxide (SPIO) nanoparticles with strong T2*-specific 
signal extinctions are widely used for labelling of different cell types [220-225]. SPIOs 
can be incorporated easily by endocytosis without requirement of transfection agents 
which could affect the viability of cells [226]. It was shown that DCs can be labelled 
as well effectively with SPIO and successfully detected via MRI [226-231]. Thus, MRI 
in combination with SPIOs might be a suitable, clinically feasible modality to monitor 
the migration behaviour of implanted cells in vivo.  
1.7. Areas of research within this thesis 
The thesis presented herein is divided into the following four main fields.  
• In the first part of the thesis, basic research on the canine HMGB1 and RAGE 
concerning the analysis of expression patterns, structural and functional 
characterisation was carried out. In detail, the naturally occurring splice 
variants of the RAGE were characterised and the expression RAGE and 
HMGB1 in canine lymphoma was analysed. In addition in silico sequence 
homology analyses of the canine cytokines IL-1α, IL-1β, and TNF-α to several 
other mammalian species were performed.  
• The second topic deals with the establishment of two novel transfection 
methods using fs-laser based opto-perforation on the one hand and the 
application of positively charged AuNPs in combination with DNA on the other 
hand.  
• The focus in the third part lies on the functional analysis of modified cells. 
Herein the induction of HMGB1 secretion from a mammary epithelial cell line 
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by cytokine stimulation and the response of canine B-cell lymphoma cells to 
CpG-oligonucleotide DSP30 and IL-2 stimulation are presented.  
• The last topic of this thesis introduces methodologies for the non-invasive in 
vivo imaging of cells including the generation of antibody fragments targeting 
canine DCs and cell tracking of SPIO nanoparticle labelled cells via MRI. 
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2. Materials and Methods 
2.1. Cell culture  
2.1.1. MTH53A 
The MTH53A canine mammary cell line, derived from epithelial healthy canine 
mammary tissue, was provided by the Centre for Human Genetics, University of 
Bremen, Bremen, Germany. The cells were cultivated in medium 199 (Gibco, 
Karlsruhe, Germany) supplemented with 10 % heat-inactivated fetal calf serum (FCS) 
(PAA Laboratories GmbH, Coelbe, Germany), 200 U/ml (U; unit) penicillin and 
200 ng/ml streptomycin (Biochrom AG, Berlin, Germany).  
2.1.2. CD34+ human umbilical cord blood stem cells (hUCBCs) 
CD34+ selected and expanded hUCBCs were provided by the department of 
Neurology, Hannover Medical School, Hannover, Germany. The cord blood was 
obtained from healthy pregnant women with non-complicated pregnancies at 
spontaneous term-deliveries (38-40 weeks of gestation) or by Caesarean section 
after informed written consent, respectively, as approved by the Institutional Review 
Board, project #3037 on June 17th, 2006.  
 
2.2. In vitro SPIO cell labelling 
Cell labelling was performed with the commercially available superparamagnetic iron 
oxide (SPIO) suspension ENDOREM® (Guerbet S.A., Roissy, France). This infusion 
suspension contains particles with an approximate size of 80 to 150 nm and has a 
total iron content of 11.2 mg/ml.  
A total of 5X106 MTH53A cells or CD34+ hUCBCs was seeded in a 25 cm2 cell 
culture flask with 5 ml of the respective cultivation medium. For labelling, 41.15 µl 
SPIO suspension (=130 pg iron oxide nanoparticles/cell) was added to the seeded 
cells followed by an overnight incubation at 37°C in 5 % CO2. After SPIO incubation, 
the viability of the labelled cells and unlabelled cells as controls was assessed by 
trypan blue staining.  
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2.3. Prussian blue staining  
After SPIO labelling, cells were fixed with 4 % paraformaldehyde, washed with 1X 
Phosphate Buffered Saline (PBS; Biochrom AG, Berlin, Germany) and incubated with 
a 1:1 solution of 5 % potassium ferrocyanide and 5 % hydrochloric acid for 30 min. 
The ferric iron (iron(III) oxide; Fe2O3) of the intracellular SPIO particles reacts 
with potassium ferrocyanide to form ferric ferrocyanide (= Prussian blue), a 
water-insoluble, blue precipitate. A final washing step with 1x PBS was performed 
before visualization of the internalized particles was carried out under light 
microscopy.  
 
2.4. Agar gel phantom construction for in vitro MRI scans  
For ex vivo MRI detection of SPIO-labelled cells, 250 ml of a hand-warm bubble-free 
1 % agar (Carl Roth GmbH & Co. KG, Karlsruhe, Germany) solution (in dH2O) were 
prepared and put into an empty pipette tip box (Greiner Bio-One, Frickenhausen, 
Germany). For generation of sample wells, an unskirted 96-well PCR plate 
(Eppendorf AG, Hamburg, Germany) was placed onto the surface of the liquid agar 
solution. After polymerisation of the agar, the 96 well-plate was removed and the 
sample wells were ready for cell loading.  
The SPIO-labelled cells were trypsinised after incubation with SPIOs and the cell 
number was determined. Defined numbers of cells were aliquoted into 1.5 ml cups 
(Eppendorf AG, Hamburg, Germany) as indicated in the results. The aliquoted cells 
were centrifuged for 10 min at 1,000 rpm (room temperature), the supernatant was 
discarded and the pellet was resuspended in 30 µl of hand-warm 4 % gelatine 
(AppliChem, Darmstadt, Germany)/dH2O solution. The cell-gelatine mixture was 
pipetted into the wells of the agar gel phantom and air bubbles were removed. The 
phantom was cooled at 4°C until the gelatine was solidified. As controls, additionally 
to unlabelled cells, 1.0 µl or 1.5 µl SPIO solution (1.0 T MRI and 7.0 T MRI, 
respectively) and 30 µl culture medium were prepared by mixing 30 µl of the 4 % 
gelatine solution and loading the samples into the wells of the agar gel phantom. 
Finally, to embed the loaded samples evenly in the agar phantom, the top was 
covered with 1 % agar gel solution. After polymerisation, the construct was stored at 
4°C until MRI analysis.  
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2.5. In vivo experiment with SPIO labelled CD34+ hUCBCs  
In vivo imaging of SPIO-labelled hUCBCs was performed in a transgenic mutant 
SOD1-ALS mouse. The G93A-ALS mouse model (B6SJL-Tg(SOD1-G93A)1Gur/J) is 
bred and maintained at the animal facility of Hannover Medical School.  
The SPIO-labelling of the cells was carried out as described in the ‘In vitro SPIO cell 
labelling’ section. The injection of the SPIO-labelled hUCBCs in the SOD1-ALS 
mouse was performed by Prof. Dr. Susanne Petri of the Department of Neurology, 
Hannover Medical School, and is described in the corresponding publication 
(Willenbrock et al., 2012b; Journal: IN VIVO).  
 
2.6. In vitro and in vivo MRI scan parameters  
2.6.1. In vitro MRI 
The scans of the prepared agar gel phantom, loaded with SPIO-labelled cells and 
respective controls, were performed in a clinical whole-body MR imaging system at 
1.0 T (Magnetom Expert, Siemens Healthcare, Erlangen, Germany) and a Bruker 
Pharmascan 70/16 7.0 T MR-tomograph for small laboratory animals (Bruker BioSpin 
MRI GmbH, Ettlingen, Germany).  
For 1.0 T analysis, a T2*-weighted gradient echo fl2d 20 sequence with a repetition 
time (TR) of 800 ms and an echo time (TE) of 26.0 ms, slice thickness of 2.0 mm, flip 
angle (FA) of 20°, field of view (FoV) of 201X230, 168X256 and two repetitions was 
used and the data analysis was carried out by dicomPACS version 5.2 (Oehm and 
Rehbein, Rostock, Germany).  
To scan the agar gel phantom in the 7.0 T MRI, an 8 cm volume resonator designed 
for MRI analysis of rats was used. The agar gel phantom was trimmed with a scalpel 
to fit into the 8 cm volume resonator. The parameters for the 7.0 T scan were as 
follows: T2*-weighted flash 2D sequence, TR/TE = 200/20, slice thickness 2.0 mm, 
FA = 90°, one repetition. 
Data were analysed using ImageJ, version 1.41 (NIH, Bethesda, MD, USA) extended 
by the Bruker Opener plugin version 2008/04/22 (Fraunhofer Institute for Biomedical 
Engineering, St. Ingbert, Germany).  
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2.6.2. In vivo MRI  
In vivo MRI was performed by Dr. Martin Meyer, Institute of Laboratory Animal 
Science and Research Cluster of Excellence ‘REBIRTH’ (AG36), Hannover Medical 
School, on a 7.0 T Bruker Pharmascan 70/16 (Bruker Biospin) equipped with a 6 cm 
volume resonator using Paravision 5.0. A T2* multi-gradient echo (MGE) with the 
following parameters was used: TR = 1500 ms, TE = 9 ms, FA = 30°, slice 
thickness = 1 mm. The G93A-ALS mouse was scanned at day 0 (injection day) and 
day 4 to detect the injected SPIO-labelled cells and to analyse if cell migration could 
be visualized.  
 
2.7. PCR and DNA cloning  
PCR amplification of DNA fragments was done using gene specific primers and 
GoTaq flexi DNA polymerase (Promega, Mannheim, Germany) according the 
manufacturers’ instructions in a Thermoblock Mastercycler Gradient (Eppendorf AG, 
Hamburg, Germany) or a Trio Thermoblock 48 (Biometra GmbH, Göttingen, 
Germany). The PCR conditions varied depending on the annealing temperatures of 
the used primers and the fragment length of the amplified PCR product.  
The amplified PCR products were separated on a 1.5 % agarose gel, eluted using 
QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) and ligated into the 
corresponding expression vector.  
The ligated expression vectors were transformed into thermocompetent Escherichia 
coli (E. coli) DH5α bacteria cells (Invitrogen AG, Carlsbad, CA, USA) as described by 
Inoue et al. (1990). For long-term storage, glycerol stocks were prepared by the 
addition of 1 ml bacteria culture into sterile aliquots of 1 ml 60 % glycerol and frozen 
at -80°C.  
Plasmid isolation was done using QIAprep Spin Miniprep Kit (Qiagen, Hilden, 
Germany) following the manufacturers’ protocol. Verification of the constructed 
plasmids was done by double restriction digest with suitable restriction enzymes and 
sequencing (Eurofins MWG GmbH, Ebersberg, Germany).  
Sequence data analysis was done using DNASTAR Lasergene software (DNASTAR 
Inc., Madison, WI, USA). Large scales of plasmids were isolated using the 
PureYield™ Plasmid Maxiprep System (Promega, Madison, WI, USA).  
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2.8. Mammalian expression vector constructs  
2.8.1. pIRES-hrGFP II expression vectors 
Different variants of recombinant pIRES-hrGFP II (Stratagene, La Jolla, CA, USA) 
vector constructs were generated, carrying the hrGFP gene (pIREShrGFP) and the 
gene of interest. The bicistronic expression cassette of the different constructed 
vectors permits the simultaneous but separate expression of the inserted genes of 
interest and of hrGFP showing successful transfection of the cells with the respective 
vector by green fluorescence.  
2.8.1.1. pIRES-hrGFP II-rHMGB1+FLAG 
This expression vector variant contains the canine HMGB1 coding sequence (CDS) 
(GenBank ID: AY135519.1) without the terminal stop codon resulting in an HMGB1 
fusion protein with a recombinant short 3x FLAG peptide sequence at its C-terminal 
part to differentiate via immunohistochemistry between endogenous and expressed 
recombinant HMGB1 protein (rHMGB1+FLAG).  
DNA fragments were amplified by PCR (forward primer: EcoRI-B1-CFA-FWD, 
5’-GGAATTCCACCATGGGCAAAGGAGA-3’; reverse primer: NotI-B1-CFA-REV, 
5’-GCGCGGCCGCTTATTCATCATCATC-3’).  
Cloning of the PCR amplicons into the pIRES-hrGFP II expression vector was 
performed as described in the ‘PCR and DNA cloning’ section. Verification of the 
constructed plasmids was done by NotI/EcoRI double restriction digest and 
sequencing.  
2.8.1.2. pIRES-hrGFP II-rHMGB1  
This vector contains the complete HMGB1 CDS (GenBank ID: AY135519.1) with its 
terminal TAA stop codon and was constructed to make sure that the 3x FLAG-tail has 
no effect on the function of the recombinant HMGB1 (rHMGB1) protein.  
DNA fragments were amplified by PCR (forward primer: EcoRI-B1-CFA-FWD, 
5’- GGAATTCCACCATGGGCAAAGGAGA-3’; reverse primer: NotI-B1-CFA-Rev/-
TAA, 5’-AAGAATGATGATGATGAAGCGGCCGCGC-3’).  
Cloning of the PCR amplicons into the pIRES-hrGFP II expression vector was 
performed as described in the ‘PCR and DNA cloning’ section. Verification of the 
constructed plasmids was done by NotI/EcoRI double restriction digest and 
sequencing.  
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2.8.1.3. pIRES-hrGFP II-eIL-12  
DNA encoding for eIL-12 (Vetsuisse-Faculty, University of Zürich) was amplified by 
PCR (forward primer: NotI_IL-12_f, 5’-CGGCGGCCGCATATGTGCCCGCCGCGC-3’; 
reverse primer: NotI_IL-12_r, 5’-CGGCGGCCGCAACTGCAGGATACGG-3’). The 
DNA contains the p35 and p40 IL-12 subunit cDNAs (p35: Acc. No. Y11129; p40: 
Acc. No. Y11130) separated by an IRES element, both IL-12 subunits are translated 
separately and then processed by the cell to a joint complex.  
Cloning of the PCR amplicons into the pIRES-hrGFP II expression vector was 
performed as described in the ‘PCR and DNA cloning’ section. Verification of the 
constructed plasmid was done by NotI restriction digest and sequencing. 
2.8.2. HMGB1-GFP fusion protein expressing vector  
The pEGFP-C1-HMGB1 expression vector, containing the complete coding 
sequence of the canine HMGB1 gene, was constructed and provided by Dr. Andreas 
Richter, Centre for Human Genetics of the University of Bremen, Germany. 
Expression of this vector leads to the formation of a HMGB1-GFP fusion protein. The 
protein coding sequence of the canine HMGB1 was amplified by PCR (forward 
primer: EcoRI-B1-CFA-FWD, 5’-CGGAATTCCACCATGGGCAAAGGAGA-3’; reverse 
primer: KpnI-B1-CFA-REV, 5’-GATGATGATGAATAAGGTACCGC-3). Cloning of the 
PCR amplicons into the pIRES-hrGFP II expression vector was performed as 
described in the ‘PCR and DNA cloning’ section. Verification of the constructed 
plasmid was done by EcoRI/KnpI double restriction digest and sequencing.  
 
2.9. Transient transfection  
2.9.1. FuGENE® HD transfection  
The transient transfection assays were performed in 6-well plates with approximately 
3×105 or 4×105 cells per well and 2 ml medium. An amount of 2 µg of the 
corresponding vector constructs was transfected into MTH53A cells according to the 
manufacturer’s instructions using 3 or 5 µl in 100 µl H2O FuGENE® HD (FHD) 
transfection reagent (Roche, Mannheim, Germany). For details concerning the used 
cell number and volume of FHD reagent c.f. the publications of Durán & Willenbrock 
et al. (2011) and Willenbrock et al. (2012). 
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2.9.2. Gold nanoparticle (AuNP) and magnet-assisted transfection (MATra)  
In comparison to the conventional FHD transfection method, five additional different 
transfection protocols were evaluated:  
- Commercially available AuNPs (Plano-AuNP; 20 nm; Plano GmbH, Wetzlar, 
Germany) combined with FHD  
- Stabilizer-free PLAL-AuNP (size 1 (d50 = 28.5 nm and d90 = 43.4 nm 
hydrodynamic sizes; 14 ± 3 nm Feret diameter) combined with FHD 
- Stabilizer-free laser-generated PLAL-AuNP size 2 (d50 = 52.4 nm and 
d90 = 78.6 nm hydrodynamic sizes; 41 ± 8 nm Feret diameter) combined with 
FHD 
- MATra using MA Lipofection Enhancer (PromoKine, Heidelberg, Germany) 
- MATra using MATra-A Reagent (PromoKine, Heidelberg, Germany)  
 
These transfection methods were performed in the co-publication of Durán & 
Willenbrock et al. (2011) and carried out by Carolina Durán. The PLAL-AuNP were 
generated and provided by Dr. Annette Barchanski (Laser Zentrum Hannover e.V., 
Hannover, Germany) and Prof. Dr. Stephan Barcikowski (Chair of Technical 
Chemistry I, University of Duisburg-Essen and Center for Nanointegration 
Duisburg-Essen (CeNIDE)). Details concerning the different transfection methods 
and the generation of PLAL-AuNPs can be found in the relevant publication. 
 
2.10. Transfection efficiency analyses 
2.10.1. Fluorescence microscopy  
The transfected MTH53A cells were incubated for 48 h in culture medium. After 
incubation, the cells were washed with 1x PBS, fixed with phosphate-buffered 
formaldehyde (4 %, pH 7.4, 10-15 min) at room temperature and washed again with 
1x PBS. Nucleic DNA was stained using Vectashield Mounting Medium with DAPI 
(4’-6-diamidino-2-phenylindole, Vector Laboratories, Burlingame, CA, USA) and the 
uptake of plasmid DNA was verified by fluorescence microscopy using an Axioskop 
microscope or Axio Imager.Z1 fluorescence microscope (both Carl Zeiss 
MicroImaging GmbH, Jena, Germany).  
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2.10.2. Flow cytometry for transfection efficiency analysis  
In order to determine the transfection efficiency, GFP expression of 
pIRES-hrGFP II-rHMGB1+FLAG and pIRES-hrGFP II-eIL-12 transfected MTH53A 
cells was analysed measuring green fluorescence by flow cytometry in comparison to 
untransfected native MTH53A cells.  
The flow cytometry analyses were carried out by Carolina Durán. Details can be 
found in the relevant publication of Durán & Willenbrock et al. (2011).  
 
2.11. Induction of HMGB1 release by cytokine stimulation  
Approximately 400,000 MTH53A cells were plated in 6-wells and transfected as 
described previously with the pIRES-hrGFPII-rHMGB1+FLAG vector construct to 
differentiate between the recombinant HMGB1 (rHMGB1+FLAG) and endogenous 
HMGB1 (eHMGB1). To induce the release of HMGB1 the cells were stimulated 24 h 
after transfection with 50 ng/ml canine TNF-α (R&D Systems, Minneapolis, USA) or 
100 U/ml canine IFN-γ (R&D Systems, Minneapolis, USA) for different time periods 
(6, 24, 48 h) at 37°C and 5 % CO2. After incubation the conditioned medium and the 
MTH53A cells were harvested for HMGB1 Western blotting and HMGB1 ELISA.  
 
2.12. Live cell imaging using laser scanning microscopy  
Live cell imaging of pEGFP-C1-HMGB1 transfected MTH53A cells was performed for 
visualization of HMGB1 release after stimulation with TNF-α.  
400,000 MTH53A cells were seeded in glass-bottom-dishes (MatTek Corporation, 
Ashland, USA). Cultivation and transfection were performed as described previously. 
24 h after transfection the cells were stimulated with 50 ng/ml canine TNF-α (R&D 
Systems, Minneapolis, USA) for induction of HMGB1 release. Live cell imaging was 
performed at the Laser Zentrum Hannover e.V. (LZH) for 50 h on an uniquely 
modified multiphoton laser scanning system (Zeiss Axiovert S100) consisting of a 
femtosecond-laser system (Chameleon Ultra II, Coherent Inc., tuneable wavelength 
690 nm-1040 nm; femtosecond = fs, 10-15 sec.) and a custom built scanning and 
detection module. Used parameters: 37°C, 5 % CO2, 900 nm wavelength, 2.71 V 
amplifier voltage, 8 mW (80 Mega-Hertz) pulse energy. Images were recorded in 
30 µm 3D-stacks with 1.5 µm layer distance and 256 x 256 pixel resolution all 
30 minutes.  
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2.13. Protein analyses  
2.13.1. SDS PAGE and HMGB1 Western blot  
48 h after transfection and stimulation of MTH53A cells the cell-conditioned medium 
was harvested and the adherent cells were lysed using cell lysis buffer (50 mM Tris, 
pH 7.8, 150 mM NaCl, 1 % Nonidet P-40). Cellular debris was removed by 
centrifugation for 10 min at 1000 rpm and the supernatants were collected.  
The presence of recombinant and endogenous HMGB1 in the harvested 
cell-conditioned medium or in lysed MTH53A cells was assayed before and after 
cytokine treatment by Western blotting analysis and quantified using the HMGB1 
ELISA Kit II (Shino-Test Corporation, Kanagawa, Japan).  
For Western blot analysis equal volumes of the harvested samples were heated for 
5 min at 95°C in reducing sample buffer, fractioned by 
sodiumdodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (4 % stacking 
gel, 12 % running gel) and transferred to a polyvinylidene difluorid (PVDF) membrane 
with 0.2 µm pore size (PALL Corporation, New York, USA) in order to examine the 
protein biosynthesis of recombinant HMGB1. Membranes were probed using a 
1:5,000 dilution of primary HMGB1 antibody [HAP46.5] (Abcam plc, Cambridge, UK) 
and 1:10,000 dilution of goat anti mouse IgG (H&L):HRP (AbD Serotec, 
Martinsried/Planegg, Germany) secondary antibody (HRP; horseradish peroxidase). 
To exclusively detect recombinant rHMGB1+FLAG protein, a monoclonal 
ANTI-FLAG® M2-Peroxidase (HRP) antibody (Sigma-Aldrich Corp., St. Louis, MO, 
USA) was used in a dilution of 1:10,000. Visualisation was done by 
chemiluminescence using 3.3’-diaminobenzidine (DAB) substrate (Sigma-Aldrich 
Corp., St. Louis, MO, USA).  
2.13.2. HMGB1 enzyme-linked immunosorbent assay (ELISA)  
To determine the HMGB1 level in the cell-conditioned medium and MTH53A cell 
lysates after cytokine stimulation the Shino-Test HMGB1 ELISA Kit II was used 
according to the manufacturer’s instructions.  
The samples were concentrated before ELISA measurement from 200-450 µl lysate 
and 500 µl medium to 20 µl end volume via 10 kilo Dalton (kDa) Roti-Spin Midi-10 
columns (Carl Roth GmbH, Karlsruhe, Germany). The absorbance of the performed 
ELISA was read at 455 nm in a Synergy HT multi-detection microplate reader 
(BioTek Instruments GmbH, Bad Friedrichshall, Germany) using KC4 software 
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(Kineticalc for Windows, version 3.4, BioTek Instruments GmbH). The levels of 
HMGB1 were calculated with reference to standard curves of purified recombinant 
HMGB1 at various dilutions (1.25, 2.5, 5.0, 10.0, 20.0, 40.0, 80.0 ng/ml) and in 
consideration of the concentrations factors.  
2.13.3. Immunofluorescence  
The immunofluorescence analyses were carried out in collaboration with Carolina 
Durán.  
To confirm biological functionality of the recombinant proteins expressed in 
pIRES-hrGFPII-eIL-12 and pIRES-hrGFP II-rHMGB1+FLAG transfected MTH53A 
cells, immunofluorescence directed against eIL-12 and canine HMGB1 was 
performed. For transfection, the previously described FHD method was chosen. The 
microscopy for analysis of the immunofluorescence was carried out using a Leica 
DMI 6000 fluorescence microscope (Leica Microsystems GmbH, Wetzlar Germany). 
2.13.3.1. Equine IL-12 
MTH53A cells were fixed 24 h after transfection in 4 % paraformaldehyde/PBS for 
20 min at room temperature, permeabilised with Triton X-100 (Sigma-Aldrich Corp., 
St. Louis, MO, USA) and blocked. Immunofluorescence was carried out using the 
primary goat IgG anti-p35 polyclonal antibody (IL-12 p35, Santa Cruz Biotechnology, 
Inc.; Santa Cruz, CA, USA) in a dilution of 1:40 and the secondary donkey anti-goat 
antibody (IgG-TR, Santa Cruz Biotechnology, Inc.; Santa Cruz, CA) in a dilution of 
1:180.  
2.13.3.2. Canine HMGB1  
The expression of canine HMGB1 was evaluated in MTH53A cells. Cells were 
prepared as described for the equine IL-12 expression. For transfection, different 
protocols were applied which are described in detail in the corresponding publication 
of Durán & Willenbrock et al. (2011).  
Twenty four hours after transfection with tree different protocols (details of the 
protocols can be found in the corresponding publication of Durán & Willenbrock et al., 
2011), immunofluorescence was performed using an anti-HMGB1 mouse monoclonal 
antibody (HMGB1 antibody [HAP46.5], Abcam, Cambridge, UK) with a dilution of 
1:60 and a goat anti-mouse antibody (DyLightTM 549-TFP ester, Jackson 
ImmunoResearch, West Grove, PA, USA) with a dilution of 1:220.  
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2.14. Toxicity and viability analyses  
2.14.1. Cell viability staining  
Viability of 24 h TNF-α or IFN-γ pIRES-hrGFP II-rHMGB1+FLAG transfected 
MTH53A and untransfected MTH53A stimulated cells was assessed by Trypan Blue 
exclusion (Invitrogen, Carlsbad, USA), which detects necrotic cells.  
To verify if incubation with TNF-α or IFN-γ may lead to apoptosis or necrosis and 
thus possibly to a release of HMGB1, double staining with Annexin V-PE / propidium 
iodide (PI) was performed using the ‘Annexin V-PE Apoptosis Detection Kit’ 
(PromoCell GmbH, Heidelberg, Germany). This assay distinguishes between 
apoptotic and necrotic cells.  
A number of approximately 400,000 MTH53A cells was seeded in 1-well Falcon 
CultureSlides (Becton, Dickinson and Company, Heidelberg, Germany), transfected 
with pIRES-hrGFPII-rHMGB1+FLAG and treated with TNF-α or IFN-γ for 6, 24, and 
48 h as described in the section 2.11. ‘Induction of HMGB1 release by cytokine 
stimulation’. After incubation, the culture medium was replaced by 500 µl 1x Annexin 
V Binding Buffer. For detection of phosphatidyl serine exposure on the external 
leaflet of the plasma membrane during apoptosis, Annexin V-PE reagent was added 
showing an orange-red staining.  
Necrotic cell detection was performed by adding propidium iodide (PromoCell GmbH, 
Heidelberg, Germany) in a concentration of 30 µM. PI is a nucleic acid intercalator 
passing only through disturbed cell membranes staining the nuclei of necrotic cells 
with a light red fluorescence.  
The cells were incubated for 15 minutes at room temperature in the dark, 
washed  wice with 1x PBS after incubation and fixed for 10 min using 4 % 
phosphate-buffered formaldehyde (pH 7.4). The cells were analyzed by fluorescence 
microscopy using an Axioskop microscope with a rhodamine filter (Carl Zeiss, 
Oberkochen, Germany).  
2.14.2. Flow cytometry for cell toxicity analysis  
Staining with PI was used to identify the percentage of dead cells after transfection. 
The flow cytometry cell toxicity analyses were carried out by Carolina Durán. Details 
can be found in the relevant publication of Durán & Willenbrock et al. (2011).  
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2.14.3. Proliferation assay  
Proliferation of cells in response to each transfection protocol was evaluated using a 
colorimetric cell proliferation ELISA (Roche Applied Science, Mannheim, Germany) 
which measures the incorporation of 5-bromo-2-deoxyuridine (BrdU) into DNA by 
ELISA using an anti-BrdU monoclonal antibody. The absorbance was read with a 
Synergy HT multi-mode microplate reader (BioTek Instruments GmbH, Bad 
Friedrichshall, Germany) and exported with Excel 2003 software (Microsoft, 
Unterschleißheim, Germany).  
The proliferation assay was performed by Carolina Durán. Details can be found in the 
relevant publication of Durán & Willenbrock et al. (2011). 
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3. Results 
3.1. Structural and functional characterisation of HMGB1 and RAGE genes, 
proteins and associated cytokines 
The following section describes basic research on RAGE and HMGB1. The 
RAGE/HMGB1 receptor/ligand complex is described to play a key role in mediation of 
immune responses, inflammation processes, angiogenesis as well as tumour 
formation and in the genesis of other diseases. Active release of HMGB1 by various 
cell types is stimulated by ‘early’ proinflammatory cytokines like TNF-α, IL-1 or IFN-γ. 
Thus, the characterisation of cytokines inducing the secretion of HMGB1 is also 
crucial for understanding the development of diseases. An in silico sequence 
homology analysis of several mammalian IL-1α, IL-1β, and TNF-α mRNA and protein 
structures was therefore carried out and is also described in this section.  
 
I ‘Cloning, characterisation, and comparative quantitative expression analyses 
of receptor for advanced glycation end products (RAGE) transcript forms.’ 
Sterenczak et al., Gene, 2009. 
 
Besides the initial characterisation of the complete canine RAGE cDNA and a 
sequence identity comparison to the human counterpart on DNA and protein level 
done by Murua Escobar et al. in 2006, the structural appearance of this 
transmembrane receptor needs to be analysed in detail. In humans, nearly 20 
different natural occurring RAGE splice variants with C-terminal or N-terminal 
truncations, lacking of the cytosolic or transmembrane domains, were found and 
discussed to be acting as mechanisms for receptor regulation by competitive 
inhibition.  
In this study RNA isolation was carried out on a set of 17 different canine tumours, 
seven healthy tissues, four canine and three human cancer cell lines and screened 
for RAGE splice variants. Subsequently, an in silico structural analysis determining 
the putative protein outcome was performed. Additionally, the ratio of the mainly 
found transcript variants was analysed by quantitative and relative real-time PCR. 
Altogether, 24 canine and six human splice variants were characterized whereof 
14 canine and four human RAGE isoforms were not described previously in other 
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species showing various combinations of insertions of introns, partial or complete 
deletion of exons and several small nuclear polymorphisms (SNPs).  
The found RAGE transcripts could be classified in two categories at which the first 
category covers splicing variants encoding for protein forms with either the complete 
open reading frame or for soluble sRAGE lacking the transmembrane domain. Both 
variants are capable to bind extracellular ligands due to the existence of the 
N-terminally localised ligand binding immunoglobulin type V-domain.  
The second group contains transcripts being processed by alternative exon / intron 
splicing and intron insertions leading to translation of mutated ‘non-sense’ protein 
forms. The most remarkable mutation found in the analysed human and canine cell 
lines and neoplastic as well as non-neoplastic samples was the recurrent occurrence 
of an intron 1 insertion.  
For absolute real-time PCR quantification, a novel approach analysing the ratio 
between the canine functional full length or sRAGE variants and the non-sense intron 
1 insertion variant transcripts was established. The analyses showed expression of 
both categories (sense and non-sense transcripts) in all canine samples. In detail, the 
screening of non-neoplastic tissues revealed a predominant expression of the full 
length or sRAGE transcript encoding for ligand binding RAGE variants in lung, testis 
and thyroid tissue. In contrast a higher expression of the intron 1 insertion variant 
was detected in ovary, pancreas, skin and spleen. In neoplastic tissue the majority of 
the samples showed a stronger expression of the intron 1 RAGE transcript variant.  
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‘High mobility Group B1 (HMGB1) and Receptor for Advanced Glycation End Products 
(RAGE) Expression in Canine Lymphoma.’ Sterenczak et al., Anticancer Research, 2010. 
 
An imbalanced expression of HMGB1 and RAGE was reported to play a key role in 
many human and canine neoplasias being strongly associated with aggressive 
potential and progression of tumour cells. With regard to haematopoietic tumours, 
lymphoma is a commonly occurring neoplasia in dogs which has a spontaneous 
development.  
To identify factors potentially involved in the formation and progression of lymphomas, 
the expression levels of HMGB1 and RAGE were measured via relative real-time 
PCR and canine beta-glucuronidase gene (GUSB) as endogenous control. The 
samples included in this study are 22 canine lymphomas and three non-neoplastic 
lymph node samples. In detail, 15 B-cell, two T-cell, three intestinal, and two 
unidentified multicentric lymphomas, which could not be classified by flow cytometry, 
were analysed.  
The expression of HMGB1 was significantly increased in all lymphoma types in 
comparison to the control samples (intestinal lymphoma: p = 0.030; B-cell lymphoma: 
p = 0.001; T-cell lymphoma: p = 0.033) except the two lymphoma samples of 
unknown origin, where no significant difference in HMGB1 expression could be 
detected.  
In contrast to this, the RAGE expression did not change significantly within all 
lymphoma samples when compared to the non-neoplastic control lymph nodes.  
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III ‘Comparison of the human and canine cytokines IL-1(alpha/beta) and 
TNF-alpha to orthologous other mammalians.’ Soller et al., Journal of 
Heredity, 2007.  
 
Cytokines as e.g. IL-1α, IL-1β and TNF-α are described to play an important role in 
the initiation and regulation of immune responses to infectious diseases and in the 
development and progression of diseases like cancer in humans as well as dogs and 
other species. The availability of recombinant canine cytokines for development of in 
vitro and in vivo approaches is still limited. Therefore, an identity comparison to 
identify potential cross-reactivity from cytokines of other species was carried out in 
this work.  
The mRNA and protein structures of TNF-α, IL1-α, and IL1-β of several mammalian 
species (human, canine, murine, rat, ovine, equine, feline, porcine, and bovine) were 
compared and analysed basing on the presently known sequences. In addition, the 
complete mRNA structures of the IL1-α, and IL1-β mRNAs were derived by in silico 
analysis of the canine genome sequence.  
The general described cytokine identity in reference to the canine sequences were 
for the human molecules on nucleotide level 76.4 % for IL-1β, 79.6 % IL1-α, and 
90.8 % for TNF-α. The respective proteins the similarity indices were 62.8 % for 
IL-1β, 68.5 % for IL1-α, and 91.0 % for TNF-α. Comparison of murine vs. canine 
sequences revealed similarities of 43.9 % for IL1-α, 71.7 % for IL-1β, and 80.4 % for 
TNF-α. The corresponding in silico determined protein similarities were 57.1 % for 
IL1-α, 53.8 % for IL-1β, and 78.2 % for TNF-α.  
Concerning the functional domains and sequence motifs, the analyses showed that 
IL-1α, IL-1β and TNF-α have a high evolutionary conserved homology within the 
mammalian species. 
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3.2. Improvement of in vitro transfection efficiencies using novel methods  
 
In collaboration with the Laser Zentrum Hannover e.V. (LZH) within the CRC / TR37 
and the Equine Clinic of the University of Veterinary Medicine Hannover two novel 
alternative transfection methods, fs-laser based opto-perforation and the application 
of positively charged AuNPs in combination with DNA, were established and 
enhanced. The transfection efficiencies and the cell toxicity effects of these novel 
methods were evaluated.  
 
IV ‘Quantified femtosecond laser based opto-perforation of living GFSHR-17 and 
MTH53 a cells.’ Baumgart et al., Optics Express, 2008. 
 
Femtosecond laser-assisted opto-perforation of cells is a new method offering distinct 
advantages over the conventional transfection methods. Transfection using fs-laser 
pulses allows a highly specific, cell-type independent transfection with good cell 
viability after transfection and high transfection efficiencies. The cell membrane is 
exposed to a highly focussed fs-laser pulse leasing to the formation of a transient 
pore allowing diffusion of exogenous nucleic acids or other molecules into the cell.  
In this work, the optimum parameters concerning cell viability, efficiency, and 
reproducibility were evaluated to get more insight into the mechanisms of fs-laser 
transfection. The changes of the membrane potential were measured by patch-clamp 
technique on eukaryotic GFSHR-17 granulosa cells allowing to estimate the 
extracellular and intracellular volume exchanged while an transient pore is induced 
and how long this pore remains opened. The measurements revealed that the 
relative volume exchanged is 0.4-fold of the total cell volume. Viability and efficiency 
measurements were performed with different irradiation times and pulse energies by 
propidium iodide (PI) re-staining of the perforated cells as the cell membrane 
impermeable PI only enters the cells which have lost their membrane integrity. The 
results showed that a good balance between viability and efficiency is achieved at an 
irradiation time of 40 ms and 3.6 million pulses with an energy of 0.9 nJ per pulse. 
With this parameters, 90 % viable and 70 % perforated cells could be found. Those 
parameters were used subsequently to proof the functionality of fs-laser transfected 
cells. Therefore, canine MTH53A cells were transfected with a HMGB1-GFP fusion 
protein expressing vector (pEGFP-C1-HMGB1) for nucleus specific labelling and the 
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corresponding pEGFP-C1 vector without insert expressing only the GFP protein for 
total cell labelling. Fluorescence of the expressed GFP was observed 24 h and 48 h 
after the opto-perforation showing a complete cell labelling at cells transfected with 
the pEGFP-C1 vector and while transfection with the pEGFP-C1-HMGB1 led to 
specific labelling of the nucleus with HMGB1-GFP. In total, 100 to 150 cells were 
targeted by fs-laser manipulation while 30 % of those cells were determined as GFP 
positive 48 h post-transfectional.  
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V ‘Comparison of nanoparticle-mediated transfection methods for DNA 
expression plasmids: efficiency and cytotoxicity.’ Durán & Willenbrock et al., 
Journal of Nanobiotechnology, 2011. 
 
In addition to the novel transfection method using fs-laser opto-perforation, 
nanoparticles have been taken into account as well as a new possibility for achieving 
enhanced transfection efficiencies. Gold nanoparticles (AuNP) are currently focussed 
in research. Herein, a new generation of stabiliser-free AuNP generated by pulsed 
laser ablation in liquids (PLAL) as recently attracted special interest.  
The data concerning toxic potential of this new generation of PLAL-AuNP in 
combination with DNA expression vectors is still marginal. Therefore, in this study the 
transfection efficiency and cytotoxic effects of five different NP-mediated transfection 
protocols (two sizes of PLAL-AuNPs, one size of commercially available chemically 
generated AuNPs, two protocols with magnetic nanoparticles) was evaluated after 
transfection of MTH53A cells with two different eukaryotic vectors (vector backbone: 
pIRES-hrGFP II) leading to simultaneous but separate expression for a recombinant 
target protein (canine HMGB1 or equine IL-12) and the humanized renilla Green 
Fluorescent Protein (hrGFP). The results of the different protocols were compared to 
the efficiencies achieved by transfection with the conventional reagent FuGENE® HD 
(FHD). The efficiency analyses were carried out using fluorescence microscopy and 
GFP-based flow cytometry. The biological functionality of the expressed recombinant 
proteins was confirmed by immunofluorescence directed against canine HMGB1 and 
equine IL-12 after transfection. To assess the cell toxicity of each protocol, the cell 
proliferation was measured by BrdU incorporation and the percentage of PI positive 
cells was determined by flow cytometry.  
The efficiency analyses revealed that the addition of PLAL-AuNPs increased the 
transfection efficiency significantly using the pIRES-hrGFP II-eIL-12 vector (FHD: 
16 %; AuNP size 1: 28 %, AuNP size 2: 25 %) and the pIRES-hrGFP II-rHMGB1 
vector (FHD: 31 %; PLAL-AuNP size 1: 46 %; PLAL-AuNP size 2: 50 %). The 
commercial available AuNP showed only an improvement of transfection efficiency 
for the pIRES-hrGFP II-eIL-12 vector (28 %) whereas the efficiency was significantly 
lower at pIRES-hrGFP II-rHMGB1 transfections (23 %) in comparison to the 
conventional FHD protocol (31 %). No significant cytotoxic effect could be observed 
at the application of PLAL-AuNP by PI staining and the cell proliferation 
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measurement whereas the commercially available AuNP induced a significant 
increase in the percentage of PI positive cells and a negative effect on cell 
proliferation. The two protocols using magnetic nanoparticles showed no significant 
improve in the transfection efficiency but resulted in the best tolerance concerning 
cell viability and proliferation.  
The detection of protein expression via immunofluorescence after AuNP mediated 
pIRES-hrGFP II-eIL-12 and pIRES-hrGFP II-rHMGB1 transfection verified the 
functionality of the nuclear acting HMGB1 and the complex eIL-12 assembled of two 
separate subunits and the localisation of both recombinant proteins at their expected 
destination.  
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3.3. Functional analysis of modified cells 
After efficient transfection of the desired cell types, the functionality of the introduced 
DNA expression plasmids needs to be characterised. An analysis of the cellular 
responses of target cells to e.g. cytokines or other stimulating agents such as 
synthetic CpG-oligonucleotides (CpG-ODN) is necessary. Especially the protein 
secretion potential, viability and growth behaviour of these cells needs to be 
investigated in detail after stimulation.  
In the following publications, the characterisation of the HMGB1 secretion potential 
by modified canine mammary cells expressing recombinant HMGB1, and the cell 
proliferative response of canine B-cell lymphoma cells to stimulation with CpG-ODN 
DSP30 combined with IL-2 are described.  
 
VI ‘TNF-α induced secretion of HMGB1 from non-immune canine mammary 
epithelial cells (MTH53A).’ Willenbrock et al., Cytokine, 2012. 
 
The HMGB1 DNA expression vectors constructed in this study were used to serve as 
basis for the immunotherapeutic approach, which was followed within the 
CRC / TR37. This project aimed at the enhancement of anti-tumour responses of the 
host immune system by secretion of HMGB1 from genetically engineered dendritic 
cells. A crucial point to realize this approach is the ability of the modified cells to 
actively secrete the recombinant expressed HMGB1 at the targeted location 
time-dependently. This can be implemented by stimulation of the cells with ‘early’ 
proinflammatory cytokines such as TNF-α, IFN-γ, and IL-1β or bacterial LPS.  
The biofunctionality of the constructed vectors was assessed as a proof of principle in 
the canine non-neoplastic mammary cell line MTH53A due to good availability of 
these cells. As MTH53A cells are usually HMGB1-non-secreting, this cell line was 
appropriate for evaluating the HMGB1 secretion potential in response to cytokine 
stimulation.  
The two recombinant bicistronic HMGB1 expression vector constructs carrying the 
hrGFP gene and the canine HMGB1 CDS encode either for an unmodified 
recombinant HMGB1 or an HMGB1 fusion protein with a short 3x FLAG peptide 
sequence located C-terminally. The HMGB1+FLAG variant was built to allow the 
discrimination between recombinant and endogenous expressed HMGB1 via 
Western blotting. Expression of both bicistronic vectors leads to a simultaneous but 
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separate synthesis of recombinant HMGB1 and hrGFP allowing the verification of 
successful plasmid DNA uptake by visualisation of green fluorescence.  
After transfection, the release kinetics of MTH53A cells expressing recombinant 
HMGB1 were analysed by stimulation with the proinflammatory cytokines TNF-α and 
IFN-γ in a time-dependent manner (6, 24, 48 h). The secretion of HMGB1 into the 
cultivation medium was analysed via Western blotting and quantified with an 
HMGB1-ELISA. In addition, live cell laser scanning multiphoton microscopy was 
performed over a time spam of 50 h on transfected MTH53A cells expressing a 
recombinant HMGB1-GFP fusion protein in order to visualise the release of this 
HMGB1-GFP protein under TNF-α stimulating conditions.  
The transfection of both bicistronic vector constructs resulted in the expression of 
biofunctional recombinant HMGB1. The active release of recombinant HMGB1 
protein was clearly detectable with a time peak of 24 h after stimulation with 
TNF-α while IFN-γ showed to have only small effects on HMGB1 secretion. 
Quantification of HMGB1 by ELISA confirmed the findings gained by Western blotting 
leading to the highest secretion of HMGB1 after 24 h of TNF-α application. By live 
cell microscopy diffuse cell membrane structure changes, but no clear secretion of 
recombinant HMGB1-GFP was visualisable starting at 29 h and ending at 42.5 h after 
TNF-α stimulation.  
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VII ‘Cytogenetic Analysis of CpG-Oligonucleotide DSP30 plus Interleukin-2-
Stimulated Canine B-Cell Lymphoma Cells Reveals the Loss of One X 
Chromosome as the Sole Abnormality.’ Reimann-Berg et al., Cytogenetic 
and Genome Research, 2011. 
 
In the fields of vaccination and immunomodulation, various CpG-ODN are in focus as 
immunotherapeutic agents due to their potential to induce humoral immune 
responses or to enhance the proliferation of cells. In this study, stimulation with the 
CpG-ODN DSP30 in combination IL-2 was utilised to generate a higher mitotic rate in 
usually slowly growing canine lymphoid cell cultures. Two short-term cultures of a 
thoracic fluid aspirate taken from a female 7 year old Retriever diagnosed with 
high-grade B-cell lymphoma were set up. One culture was set up in non-stimulative 
standard RPMI medium with 20 % FCS, L-glutamine and antibiotics. The other 
culture was prepared with the addition of DSP30 and IL-2 to the standard RPMI 
medium.  
The stimulation with DSP30 and IL-2 resulted in the generation of an adequate 
number of metaphases for cytogenetic analyses. The karyotyping of the thoracic fluid 
aspirate revealed the loss of one X chromosome as sole cytogenetic deviation.  
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3.4. In vivo imaging of cells 
To establish approaches targeting at cancer immunotherapy using modified cells, 
reliable and well-tolerated techniques for non-invasive tracking and imaging of the 
migration of administered cells in vivo are needed. Therefore, two different strategies 
implementing specific in vivo detection were followed within this thesis being also of 
significant value for further development of the immunotherapeutic approach followed 
within the CRC/TR37.  
 
VIII ‘Generation of recombinant antibody fragments that target canine dendritic 
cells by phage display technology.’ Fitting et al., Veterinary Comparative 
Oncology, 2011. 
 
The use of autologous modulated DCs for cancer immunotherapy leading to the 
induction of specific anti-tumour responses is currently of great interest in research. 
The success of these therapeutic approaches is dependent on the effectiveness of 
the cells to migrate to their final destination, where immune responses are induced. 
In humans, DC specific antibodies are used to localise and quantify the applied DCs 
in the organism, but the availability of such antibodies is limited for dogs.  
Therefore, in this study highly specific single-chain variable fragment (scFV) 
antibodies specifically binding to canine DCs were generated and characterised by 
phage display technology. A stringent subtractive three-step panning strategy was 
carried out beginning with a negative selection on canine PBMCs and followed by 
positive selection on canine DC membrane fragments. Between each panning round 
the selection pressure was increased by enhancing the stringency of washing 
conditions and reduced antigen concentrations. The enrichment for a phage 
population specifically binding canine DCs was documented in polyclonal phage 
ELISA. The monoclonal phage verification by ELISA and sequencing revealed a total 
of eight unique clones. Two of those clones were selected for further characterisation 
showing a six- and 20-fold affinity to canine DCs respectively in comparison to canine 
PBMCs. The two identified scFV clones were expressed as soluble periplasmic 
proteins and a scFV ELISA was performed subsequently to confirm the two clones as 
highly specific binding to functional canine DC membrane fragments.  
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IX ‘In vivo MRI of Intraspinally Injected SPIO-labelled Human CD34+ Cells in a 
Transgenic Mouse Model of ALS.’ Willenbrock et al., In Vivo. 2012.  
 
An alternative to the in vivo detection of cells with specific antibodies is the unspecific 
cell-labelling using MRI detectable SPIO nanoparticles causing strong T2* specific 
signal extinctions. Due to their high biocompatibility and low cellular toxicity, by now 
different types of SPIOs with varying sizes and surface modifications are widely used 
for labelling diverse types of cells.  
Purpose of this study was the establishment of a non-invasive modality for cell 
tracking of intraspinally transplanted CD34+ human umbilical cord blood stem cells 
(hUCBCs) in a transgenic ALS mouse model closely mimicking the 
neurodegenerative disease as it occurs in humans.  
The cell labelling was performed with the commercially FDA-approved SPIO-contrast 
agent ENDOREM® on MTH53A cells as proof-of-principle and subsequently on 
hUCBCs. The tracking efficiency of the labelled cells was determined in vitro for 
MTH53A and for hUCBCs in vitro and in vivo by 1.0 and 7.0 T MRI. The in vitro 
experiments were carried out in agar gel phantoms loaded with different numbers of 
SPIO-labelled cells.  
The in vitro detection limit with 1.0 T was determined at 100,000 MTH53A cells and 
250,000 hUCBCs while at 7.0 T 25,000 MTH53A cells were visible. Based on these 
results, in the in vivo imaging experiment 100,000 labelled hUCBCs were 
intraspinally injected into the mouse model and scanned with 7.0 T at day 0 and 4. 
The injected cells were clearly detectable at day 0 and also at day 4 a signal with the 
same intensity was present, but no cell migration could be visualised.  
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4. Discussion 
4.1. Structural and functional characterisation of HMGB1 and RAGE genes, 
proteins and associated cytokines 
Two targets focussed in this thesis are the HMGB1 and RAGE genes and proteins. 
The structural characterisation of the canine HMGB1 and RAGE was carried out 
previously by Murua Escobar et al. in 2003 for HMGB1 [24] and in 2006 for RAGE 
[25] showing for HMGB1 100 % protein identity to its human counterpart, whereas 
the comparison of the canine RAGE protein revealed a total of 77.6 % identity to the 
human RAGE. In detail, the comparison of the ligand-binding RAGE V-domain 
showed an identity of 85.7 %. The high similarity of the human and canine 
RAGE/HMGB1 complex allows the establishment of therapeutic approaches for the 
dog as animal model, which can also be used for translational oncology research in 
humans [24, 25].  
HMGB1, initially known to be a nuclear protein, is also described to exert extracellular 
function acting mainly as a ligand for RAGE and the Toll-like receptors -2, -4, and -9 
[58, 59, 100, 102]. Interaction of HMGB1 with RAGE is reported to play a crucial role 
in the pathogenesis of various diseases, immune responses, inflammation processes 
and cancer progression [118, 122, 127, 131, 150, 151, 163, 166, 170, 177, 232]. 
Besides the full-length RAGE, nearly 20 naturally occurring splicing variants of the 
receptor with either C-terminal or N-terminal truncations were identified [136-140, 
reviewed in 143]. The soluble C-terminal truncated RAGE forms are acting 
extracellular as decoy receptors for HMGB1 displacing the membrane located 
full-length protein [146], while the N-terminally truncated forms are not able to bind 
ligands without the Ig V-domain. In general, the diverse variants of RAGE are 
discussed to act as mechanisms for receptor regulation by competitive inhibition 
[reviewed in 148, 149].  
As described in the results section, (see: 3.1., publication I), Sterenczak et al. (2009) 
[233] were able to describe 14 RAGE splice variants in different tissues and cancer 
cell lines, which were not yet discovered in any species. In addition, four new splice 
variants were detected in human cell lines. Two groups of RAGE isoforms were 
classified. The first group encoded for full-length or the soluble RAGE, the second 
group included N-terminally truncated proteins lacking the capacity to bind ligands. 
The coding sequences of the second group are recurrently characterised by 
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insertions of intron 1 resulting in protein variants which have lost their function as 
competitive inhibitor due to the missing V-domain, or the CDS encodes for a 
nonsense protein. A similar variant with an intron 1 insertion was identified in 2003 by 
Yonekura et al. [138] in human endothelial cells and pericytes showing that those 
types of variants are also present in human non-neoplastic tissues. The data 
generated by Sterenczak et al. confirm and complement the findings by 
Yonekura et al. providing information on the expression of intron 1 insertion variants 
and other RAGE isoforms in human neoplastic samples as well as in canine 
non-neoplastic tissues, tumour samples, and cancer cell lines.  
Additionally, the expression ratio between the RAGE intron 1 variants and the 
ligand-binding RAGE transcripts was quantified in the study by Sterenczak et al. in 
the canine non-neoplastic tissue, tumour samples and the cell lines showing 
expression of both forms in all samples. In detail, the healthy tissues of lung, testis, 
and thyroid gland showed a higher amount of the ligand-binding transcripts 
compared to the RAGE intron 1 variants. In contrast, the majority of the examined 
tumour samples and tumour cell lines showed a greater quantity of N-terminally 
truncated RAGE intron 1 transcripts. The putative protein of this splice variant would 
result in a truncated transmembrane RAGE lacking the ligand-binding V-domain. The 
human intron 1 variant is discussed to be non-translated and considered to be 
targeted to nonsense-mediated decay (NMD), as it failed to produce an 
immunoreactive band in Western blot analyses [143, 147, 234]. This theory might 
also be valid for the canine intron 1 variants and needs to be confirmed on protein 
level. During the performed study in 2009, the detection of RAGE proteins in the dog 
was challenging due to the lack of specific antibodies. Recently, antibodies detecting 
specifically the canine RAGE [235] as well as an ELISA for quantification of canine 
sRAGE (Supplier: Shanghai BlueGene Biotech Co. Ltd.) are available, and offer new 
possibilities for characterisation of canine RAGE expression on protein level.  
The exact biological role of the diverse soluble and membrane bound RAGE variants 
in humans and dogs remains still to be elucidated in detail. Recent studies reported 
that deregulations of the naturally occurring functional RAGE isoform are associated 
with RAGE mediated diseases in humans. Especially circulating soluble RAGE levels 
in human serum are in the current focus of RAGE research. Soluble RAGE was 
detected in human serum in a strong correlation with the pathologic state of various 
RAGE-related diseases [reviewed in 143, 148, 236, and 237].  
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In terms of cancer, the expression of endogenous sRAGE was firstly shown to be a 
suitable prognostic tumour marker for the classification of the malignancy of 
chondrosarcomas [238]. Other studies reported that soluble RAGE is inversely 
associated with human breast [239], lung [240], liver [241], pancreatic [242] and 
colon cancer [243] and may contribute to disease progression.  
In general, RAGE splicing seems to be more complex than initially expected due to 
the presence of the wide range of structurally different RAGE splicing variants found 
in humans, rodents, as well as in dogs [233]. The findings of the present study 
contribute to understand the complexity in which deregulation or aberration of the 
splice variants play a role in the pathogenesis of RAGE-mediated diseases [233].  
As previously described, deregulations of RAGE and HMGB1 were found in various 
human cancer types [reviewed in 165, 180], but HMGB1 and RAGE expression 
analyses in canine tissues and especially neoplasias are still rare [24, 25, 94].  
As lymphoma is a commonly occurring neoplasia in dogs and resembles the human 
disease closely, during the work on this thesis the expression of HMGB1 and RAGE 
was analysed for potential deregulations in 23 canine lymphomas and control 
samples of healthy dogs. The analysis revealed a highly significant up-regulation of 
HMGB1 in all lymphoma samples in comparison to the samples of healthy dogs 
whereas the expression of RAGE was not significantly different in comparison to the 
controls [244] (see: results section 3.2., publication II). The findings concerning 
HMGB1 expression are consistent with the results generated in a previous study by 
Meyer et al. in which high HMGB1 levels in human NHL were reported [96]. In 
addition, high levels of HMGB1 in serum of lymphoma bearing dogs were 
detected [97].  
Up to now, besides the herein presented study by Sterenczak et al. (2010) [244], 
RAGE expression analysis in lymphoma was only carried out in one study using 
multi-tumour tissue microarray (TMA) technology detecting merely a borderline 
positive staining against specific RAGE [181]. Although this result was not further 
discussed by the authors, it seems to be consistent with the findings by 
Sterenczak et al. indicating low levels of RAGE in lymphoma [244].  
HMGB1 signalling is not solely mediated via RAGE, but also by binding to TLR 
receptors such as TLR-2 and TLR-4 [58, 59, 101]. Thus, TLRs should also be 
considered regarding lymphoma development and progression, especially in the 
context of tumour angiogenesis and the existent linking to the increased expression 
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of the vascular endothelial growth factor (VEGF) in lymphoma cells [180, 244-246]. 
The expression or overexpression of TLR receptors found in different tumour types 
underlines this assumption [247]. Genotyping of DNA from human lymphoma cases 
detected polymorphisms in the TLR-2 and TLR-4 genes which were hypothesised to 
increase the risk of follicular lymphoma and mucosa-associated lymphoid tissue 
lymphoma respectively [248]. Expression analyses revealed that TLR-2 is strongly 
expressed in human diffuse large B-cell lymphoma and peripheral T-cell 
lymphoma, whereas TLR-4 expression was only up-regulated in the latter one [249]. 
TLR-4 was also found to be overexpressed in mantle cell lymphoma [250]. The 
involvement of TLR receptors in the pathogenesis of lymphoma in dogs has not yet 
been examined and remains to be elucidated.  
In conclusion, the overexpression of HMGB1 in canine lymphoma strongly supports 
the assumption that similar mechanisms might be involved in the progression of the 
disease as they are existent in humans.  
In terms of structural and functional basic research on the canine HMGB1 and RAGE 
genes, the characterisation of canine cytokines being involved in the signal 
transduction of HMGB1-mediated effects is also fundamental for understanding the 
involvement in pathogenic processes.  
HMGB1 in its cytokine function plays a major role in the induction of immune system 
reactions by activation of cells and initiation of inflammatory responses. Immune cells 
like monocytes, macrophages and DCs, but also other cell types, have been reported 
to secrete HMGB1 actively triggered by LPS or classical ‘early’ response 
proinflammatory cytokines such as TNF-α, IL-1β or IFN-γ [55, 72, 75, 82-85, 251, 
252]. In turn, HMGB1 itself has the capacity to induce the cellular release of 
proinflammatory cytokines including TNF-α, IL-1α, IL-1β, IL-6, IL-8, IFN-γ and the 
chemokines MIP-1α (macrophage inflammatory protein), MIP-1β and MIP-2 [55, 58, 
72, 253, 254].  
Especially TNF-α, IL-1α and IL-1β are generally described play a pivotal role as 
potent multifunctional proinflammatory cytokines in signal transduction processes 
during host immune response and inflammation [255]. In dogs, the same key 
cytokines might also be involved in the initiation and regulation of inflammation and 
immunity responses [255]. To examine cell stimulatory effects of cytokines like the 
previously mentioned, approaches with those proteins need to be carried out. For cell 
stimulation experiments, mainly recombinant proteins are used. At the beginning of 
Discussion   
 138
this thesis, the availability of recombinant canine cytokines was poor in contrast to 
the recombinant human and murine analogues. Therefore, an in silico identity 
comparison of the canine TNF-α, IL-1α and IL-1β mRNAs to several presently known 
sequences of other mammalian species (human, canine, murine, rat, ovine, equine, 
feline, porcine, and bovine) was carried out by Soller et al. (2007) to identify potential 
cross-reactivity between species [255] (see: results section 3.1., publication III).  
The analyses revealed a highly conserved homology for all analysed cytokines 
concerning their functional domains and sequence motifs amongst the mammalian 
species included in this study. In particular, the highest identities were found between 
dog and human on protein level, with TNF-α showing an especially high similarity 
index of 91 %. The properties of the analysed cytokines are of significant value for 
the development of in vitro and in vivo stimulatory experiments with canine cells and 
can also contribute to the establishment of preclinical therapeutic approaches. At 
present, canine recombinant TNF-α, IL-1α and IL-1β are commercially available, but 
still limited to purchase just at a small number of companies and quite expensive in 
contrast to the human and murine counterparts. Thus, especially the information 
concerning the high identity of canine and human TNF-α is valuable for conducting 
canine cell stimulation analyses with the same efficiency in large experimental setups 
and within standard cell differentiations as e.g. the ex vivo expansion of canine DCs 
from canine CD34+ haematopoietic stem cells (HSC), but with much lower expenses.  
4.2. Improvement of in vitro transfection efficiencies using novel methods 
Besides the proinflammatory and tumour progressing abilities, HMGB1 in its role as 
cytokine is also described to mediate immunomodulatory effects such as triggering 
immune responses and initiation of reparative processes [182-184, 256]. A delicate 
balance of HMGB1 seems herein to be the key for the mediation of beneficial to 
pathological effects [182, 184]. The advantageous immune system activating 
properties of HMGB1 may be used to establish novel therapeutic strategies in terms 
of cancer immunotherapy.  
During this thesis, such an approach was followed within an interdisciplinary project. 
A vaccination strategy with recombinant HMGB1-secreting genetically engineered 
DCs for induction of enhanced host anti-tumour immune responses in the dog as 
model organism was aimed herein. As previously described, the highly efficient 
transfection of canine haematopoietic stem cells with HMGB1 expression plasmids 
was a crucial point within this approach. Standard methods are coming to the limits at 
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distinct cell types like stem or primary cells resulting in unsatisfactory transfection 
efficiencies of cell toxicity. Consequently, new methods showing high efficiencies and 
reduced cell toxicity effects are needed for cells being difficult to transfect.  
The principle of the femtosecond (fs)-laser based opto-perforation as alternative 
method for transfection offers distinct advantages. With this method the selective 
targeting of different types of single cells without addition of chemical reagents while 
maintaining high transfection efficiency and cell viability is possible. The fs-laser 
operates without contact, thus sterile conditions are present during the transfection 
procedure.  
Firstly, the fs-laser transfection was described by Tirlapur et al. in 2002 [207], but 
reliable data concerning the efficiency and viability were just generated in the year 
2006 by Stevenson et al. using Chinese hamster ovary (CHO) cells [208]. The 
average transfection efficiencies using a pEGFPN2 plasmid encoding for GFP were 
found to be 50 ± 10 % while the overall corrected cellular viability was 70 ± 8 % after 
transfection [208]. However, the optimum parameters in terms of cell viability after 
treatment, efficiency and reproducibility were not characterised in detail. Furthermore, 
the basic mechanism of the perforation process (lifetime of created pores, volume 
exchange during perforation) was not well understood at this time. Therefore, the 
study by Baumgart et al. (2008) investigated these issues [257] (see: results section 
3.2., publication IV). Of main interest for the forthcoming of molecular therapeutic 
approaches such as followed within this thesis, is the successful transfection of cells 
with DNA expression plasmids. As proof of principle, canine MTH53A cells were 
transfected by Baumgart et al. with either non-recombinant pEGFP-C1 vector or a 
recombinant variant encoding for an EGFP-HMGB1 fusion protein for nucleus 
specific labelling. The fs-laser transfection parameters were optimised aiming at a 
good balance between viability and efficiency. With those parameters 30 % EGFP or 
EGFP-HMGB1 positive cells were detectable 48 hours after transfection. The 
localisation of the recombinant EGFP-HMGB1 in the nucleus of successfully 
transfected cells showed nicely, that the fs-laser opto-perforation does not impair the 
biofunctionality of the introduced DNA plasmids. These results demonstrate that 
the expression of more complex proteins than EGFP and specific targeting of the 
recombinant proteins to their final destination is possible with this method. The 
efficiencies gained with the newly established parameters were lower in comparison 
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to the results by Stevenson et al. [208], but with a higher viability rate of 90 % being 
significant for the subsequent transfection of more sensitive primary cell types.  
The improvement of the fs-laser opto-perforation carried out by Baumgart et al. 
shows that a highly specific single cell targeting for transfection is possible [257]. 
However, the method is limited by its rather low throughput because the laser focus 
needs to be aligned by the operating person to every single cell.  
In this context, different approaches targeting at the automation of this process to 
generate higher a throughput are currently ongoing. One promising approach based 
on the previous findings is the gold nanoparticle (AuNP)-mediated lasertransfection 
[258-264]. This method uses ultrashort laserpulses, which are not as strongly 
focussed as in the opto-perforation method. The transient permeabilisation of the cell 
membrane is attained by the plasmonic effects which occur due to the interaction of 
AuNPs and laser radiation [260]. This novel method allows a simultaneous 
high-throughput transfection of multiple adherent as well as floating cells [259, 260]. 
Currently, high perforation efficiencies can be achieved for introduction of small 
molecules such as fluorescent dyes and fluorescent dextranes with sizes of 10 to 
2000 kDa into mammalian cells [260, 263, 264].  
An alternative novel transfection method using AuNPs differing in terms of the 
fabrication technique to the particles used in the previously described 
AuNP-mediated laser transfection was also carried out within this thesis in 
collaboration with the Equine Clinic of the University of Veterinary Medicine Hannover.  
Herein, a new generation of positively charged AuNPs was used, which were 
generated by pulsed laser ablation in liquids (PLAL) without addition of any stabilising 
agents. PLAL-AuNPs were shown to easily attract biomolecules such as single 
stranded DNA oligonucleotides [265]. First data indicated that mammalian cells can 
be efficiently transfected with DNA expression vectors in the presence of different 
sizes of PLAL-AuNP without disturbing the bioactivity of the introduced DNA [216]. 
Although the transfection efficiency was improved by adding AuNP to standard 
transfection protocols and a biofunctionality of the transfected DNA was given, 
information about the toxic potential of these particles in combination with DNA 
expression plasmids were lacking [216]. Therefore, the transfection efficiencies and 
methodology-induced cytotoxic side effects of PLAL-AuNP-mediated transfection in 
comparison to other NP-mediated and conventional methods were analysed within 
this thesis in the collaborative publication of Durán and Willenbrock et al. (2011) [266] 
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(see: results section 3.2., publication V). The transfection efficiency of two DNA 
expression plasmids with different sizes (pIRES-hrGFP II-rHMGB1: 5531 bp; 
pIRES-hrGFP II-eIL12: 7709 bp) was significantly increased by the addition of the 
physically produced PLAL-AuNP in comparison to conventional protocols, while the 
AuNPs added did not interfere with the biosynthesis of the recombinant proteins. 
Variations in the efficiencies using the same transfection protocol with different 
expression vectors could be explained by the inverse correlation between the 
construct size and the cellular uptake of DNA [267-269]. Although the PLAL-AuNP 
protocols showed the highest transfection outcome, also slightly increased cytotoxic 
effects and reduction of cell proliferation were observed. To clarify if the observed 
cytotoxic effects are caused by intolerance to the used AuNPs or to the expression 
products of the transfected recombinant expression vector constructs, further studies 
with different cell lines and expression vectors should be performed.   
In conclusion, the addition of PLAL-AuNP aiming at the improvement of the 
achievable transfection efficiency provides an interesting novel tool for DNA 
transfection approaches in general. Nevertheless, as stated before, considering the 
observed AuNP induced side effects, the attainable enhancement on transfection 
efficiency should critically be evaluated for the respective target cell type and vector 
construct.  
4.3. Functional analysis of modified cells 
Various types of cells including monocytes, activated macrophages, mature dendritic 
cells, and natural killer cells [55, 73, 74, 192] are capable to secrete HMGB1 actively, 
which in turn stimulates proinflammatory cytokine synthesis [62, 72]. In general, 
active HMGB1 release was shown to occur in a delayed manner ranging from 8 to 20 
hours following most effective stimulation with LPS, TNF-α or IL-1β, [55, 62, 75].  
To establish an immunotherapeutic approach on the immunostimulating beneficial 
effects of HMGB1, the functionality of recombinant HMGB1 expression vector 
constructs needs to be characterised after transfection of the targeted cell types. 
Further, a detailed analysis of the release kinetics of the desired recombinant 
HMGB1 protein from the genetically engineered cells in response to certain stimuli is 
essential in order to achieve a directed release of HMGB1 at the targeted destination.  
The functionality of two bicistronic HMGB1 expression vector construct variants was 
therefore verified by transfection of the canine mammary epithelial cell line MTH53A 
within this thesis by Willenbrock et al. (2012b) (see: results section 3.3., publication 
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VI) [270]. In the following, the HMGB1 secretion potential and the release kinetics of 
transfected recombinant HMGB1 expressing canine mammary cells were assessed 
after stimulation with TNF-α or IFN-γ by Western blot and quantified with an HMGB1 
ELISA. The biofunctionality of both bicistronic vectors was successfully demonstrated 
by fluorescence microscopy and Western blotting resulting in the expression of 
hrGFP and recombinant HMGB1. These results were essential for the subsequent 
cytokine stimulation experiments with TNF-α or IFN-γ. Unstimulated transfected 
MTH53A cells were shown not to secrete HMGB1 spontaneously, whereas a clearly 
time-dependent release kinetic of recombinant HMGB1 into the cell culture medium 
could be demonstrated upon stimulation with TNF-α. The peak release was 
observed after 24 hours. A shorter stimulation time of 6 hours seems to be 
insufficient for an effective induction of active HMGB1 secretion from MTH53A cells. 
In comparison to the 24 hour TNF-α stimulation results, a slightly reduced level of 
HMGB1 was detectable after 48 hours which indicates that an extended stimulation 
with TNF-α does not induce an increased HMGB1 secretion. The reduction of 
extracellular HMGB1 after 48 hours might be explained by proteolytic degradation. 
HMGB1 was shown to be rapidly degraded by plasmin due to its lysine-rich structure 
[271] and plasmin is known to be present in mammary epithelial cells [272]. Thus, 
this theory might also be applied to the mammary epithelial cell line MTH53A.  
The stimulation with IFN-γ showed to have only small effects on HMGB1 secretion 
after 24 hours with a slight increase after 48 hours. A study by Rendon-Mitchell et al. 
showed similar results in which peak levels of HMGB1 were observed after 32 hours 
in the culture medium of macrophage cultures after IFN-γ application. The reduced 
efficiency of IFN-γ to induce HMGB1 release may be explained by the partial 
regulation of IFN-γ through a TNF-α dependent mechanism [251].  
To confirm that the induced HMGB1 release was specific and not due to cell death, 
cell viability staining was performed at which no increase of dead cells was 
detectable after cytokine stimulation in comparison to untreated controls. By the cell 
viability staining a necrotic or apoptotic effect caused by excessive levels of 
extracellular HMGB1 was also excluded.  
In conclusion, the findings gained within this study show that mammalian cells 
transfected with HMGB1 expression vectors can be stimulated with TNF-α in a 
time-dependent manner to actively release recombinant HMGB1 [270]. Further, the 
HMGB1 release kinetics are in agreement with previous reports which signify that 
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HMGB1 is secreted at highest levels after 18-24 hours of TNF-α stimulation [55, 75, 
84]. This delayed HMGB1 release opens a time window of approx. 24 hours leaving 
an extended scope for the implementation of immunotherapeutic approaches using 
e.g. HMGB1 transfected DCs such as targeted within the CRC / TR37. The release 
kinetics of HMGB1 from such genetically engineered DCs need to be carefully 
characterised as well. HMGB1 is known to mediate its proinflammatory effect by 
activating the release of ‘early’ cytokines [55, 72, 253]. Thus, the release profile of 
those cytokines also needs to be focussed in immunotherapeutic approaches. 
Recently, this can be easily performed for dogs as well due to the availability of the 
‘MILLIPLEX MAP Canine Cytokine / Chemokine Magnetic Bead Panel’ (EMD 
Millipore Corp., Billerica, MA, USA) detecting 13 different key cytokines 
simultaneously in one sample based on the Luminex® xMAP® platform (Luminex 
Corporation, Austin, TX, USA). Another point, which may be drawn closer into 
consideration, is the fact that HMGB1 underlies posttranslational modifications like 
e.g. the oxidative state of HMGB1 that modulates its activity [69]. It is necessary to be 
investigated if recombinant HMGB1 expressing cells are capable to secrete the 
recombinant protein in the proinflammatory acting reduced form, or if it is possible 
that the cells release oxidised HMGB1 which was described to be rather 
tolerogenic [69].  
Besides cytokines, other effector molecules such as synthetic oligodeoxynucleotides 
containing the cytosine-phosphate-guanine (CpG) motif (CpG-ODN) provide the 
opportunity to stimulate cellular responses in a number of different mammals [273]. 
By binding to TLR-9 [109], CpGs have been shown to trigger strong immune system 
responses by direct stimulation of B-cells [274-276], induction of maturation and 
differentiation of DCs [277], NK cell toxicity [278], and secretion of proinflammatory 
cytokines [279]. Owing to the described immunomodulatory effects, CpG-ODN may 
be useful as non-specific immune system stimulating adjuvant serving as a 
therapeutic tool for tumour therapy, or in the modulation of allergic and infective 
responses [273]. The stimulative effect of particular CpG-ODNs can also be used for 
enhancing the mitotic activity of B-cells. For instance, the CpG-ODN DSP30 in 
combination with IL-2 has been reported to be an easy and efficient mitotic stimulus 
allowing e.g. to detect clonal abnormalities in human chronic lymphatic leukaemia 
(CLL) and B-cell lymphoid neoplasms [280-282].  
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Based on this information, within the study of Reimann-Berg et al. (2011) stimulation 
with the CpG-ODN DSP30 in combination IL-2 was used to achieve a higher mitotic 
rate in usually slowly growing canine lymphoid cell cultures (see: results section 3.3., 
publication VII) [283]. The stimulation showed that the human CpG-ODN DSP30 in 
combination with IL-2 also induces proliferative responses of canine lymphoid cell 
cultures by the generation of an adequate number of metaphases. The cytogenetic 
analyses revealed a monosomy of the X chromosome in all analysed metaphases. 
This clonal chromosome abnormality is also present in human malignancies [284, 
285]. Thus, the haematopoietic disorders in dogs may help to understand the 
significance of such chromosomal abnormalities in humans.  
In general, the CpG-ODN sequence motifs are considered to vary among mammalian 
species for induction of cellular responses [286, 287]. For example, DSP30 was 
reported to be poor in activating murine immune cells (Bauer 1999), but seems to be 
effective in dogs as demonstrated by Reimann-Berg et al. [283]. So far, the research 
concerning the identification of effective canine CpGs is still rare. Merely some 
human CpG-ODN sequences were reported to induce lymphocyte proliferation of 
canine spleen and lymph node cells in contrast to a control GpC ODN [273], and a 
specific CpG-ODN was identified to induce Th1 cytokines in canine PBMCs [286]. In 
conclusion, the potential application of CpG-ODN, for example as adjuvant 
immunotherapy, may also be valuable in veterinary medicine and for translational 
research in humans, but the specific identification of effective CpG-ODNs in canines 
is necessary [286].  
4.4. In vivo imaging of cells 
To implement cancer immunotherapeutic approaches using unmodified or modified 
cells such as gene-modified DCs to enhance immune responses, not only the 
functional analysis of the cells before implantation, but also the in vivo migration 
behaviour of the transplanted cells and their homing to the desired destination in the 
organism needs to be clarified. Therefore, well-tolerated, reliable techniques for 
non-invasive in vivo tracking over long time periods are needed. As previously 
mentioned, two different strategies for specific in vivo detection were followed during 
the work on this thesis in collaborative work packages contributing to the 
development of a cancer vaccine approach.  
The first strategy followed the utilisation of highly specific antibodies for targeting 
canine DCs in vivo. Due to the fact that the availability of such antibodies is limited in 
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dogs, recombinant single-chain variable fragment (scFV) antibodies specifically 
binding to canine DCs were successfully isolated by phage display technology within 
the study by Fitting et al. (2011) (see: results section 3.4., publication VIII) [288]. 
These antibodies provide a basis for the development of new techniques for 
immunological detection, characterisation and quantification of canine DCs due to the 
fact that present technologies for the non-invasive monitoring of DCs in vivo are 
limited [288, reviewed in 289]. The localisation and function of immune cells at the 
desired destination are up to now prevalently determined by classical non-invasive 
radioactive labelled scintigraphic imaging [198]. Other invasive methods such as 
biopsies and ex vivo cell functionality analysis allow only one ‘snap shot’ per time and 
location, but lacking to adequately reflect the distribution of the implanted cells in all 
physical dimensions [reviewed in 289, and 290]. In contrast, the non-invasive in vivo 
visualisation of cell migration would allow monitoring the therapy efficacy directly. 
Besides the classical imaging techniques, various novel in vivo imaging approaches 
with minimal toxicities are presently developed and improved, such as optical 
fluorescence and bioluminescence imaging or MRI [289]. Prospectively, the use of 
specific antibodies such as isolated by Fitting et al. [288], coupled e.g. with 
fluorescent dyes or near-infrared (NIR; 700-900 nm) fluorescent semiconductor 
quantum dots (QD), might be used for effective labelling of DCs in vivo by systemic 
administration at the desired time points. QD are recently discussed as an alternative 
to organic fluorescent dyes to be useful for long-term tracking of live cells in vitro due 
to their bright fluorescence, narrow emission, broad ultraviolet (UV) excitation, and 
high photostability [291-294]. However, QD with a cadmium selenide (CdSe) core 
were found to be significantly cytotoxic under certain conditions. The cytotoxic effect 
is caused by the release of free cadmium-ions from the QD cores during long-time 
UV light exposure in primary hepatocytes [294]. Therefore, the toxic potential of QD 
in in vivo applications must be critically evaluated. Nevertheless, tracking of tumour 
cells in mice using QD-conjugated specific antibodies against cancer biomarkers was 
successful, but in vivo imaging with QD cannot be scaled up directly to larger 
organisms due to limited optical signal penetration depth [reviewed in 295]. In this 
context, first encouraging results concerning the detection and diagnosis in patients 
with breast cancer using non-invasive NIR optical imaging devices instead of UV light 
were shown [reviewed in 295, and 296, 297].  
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The second in vivo imaging strategy is based upon unspecific cell-labelling with 
biocompatible superparamagnetic iron oxide (SPIO) nanoparticles and detection via 
MRI. Within this study, the feasibility of SPIO-labelling of MTH53A cells as proof of 
principle and of CD34+ human umbilical cord blood stem cells (hUCBCs) and their 
subsequent in vitro and in vivo MRI detection was assessed by Willenbrock et al. 
(2012a). The study revealed that the in vitro MRI detection limit at 1.0 T field strength 
was higher for SPIO-labelled MTH53A cells than for hUCBCs (see: results section 
3.4., publication IX) [298]. This might be explained by a larger cell surface size of 
MTH53A cells leading to a higher possibility of SPIO-uptake by MTH53A cells in 
comparison to hUCBCs. When comparing the 1.0 and 7.0 T in vitro data, a four-fold 
smaller number of labelled MTH53A cells was detectable at 7.0 T. This indicates that 
the filed strength seems to be not directly inversely proportional to the detectable cell 
number. The in vivo data showed a clear signal for 100,000 SPIO-labelled implanted 
hUCBCs, while at day four after transplantation into the spinal cord a signal with the 
same intensity, but no cell migration could be observed. Possibly, the duration time of 
four days for in vivo imaging was not sufficient to monitor migration of cells. Thus, a 
longer time period of e.g. two to four weeks as reported in similar studies might be 
adequate [299, 300]. Additionally, stimulation of hUCBCs with factors improving cell 
migration such as G-CSF (granulocyte colony-stimulating factor) [301-303], 
AMD3100 [303], CXCL12 (Chemokine (C-X-C motif) ligand 12) [304] or HMGB1 [66, 
305] might also improve cell migration along the spinal cord.  
In general, the dependency of the cell detection limit in correlation to the MR field 
strength is a limitation within this study. The visualisation at single-cell level is 
presently not possible by 7.0 T MRI in combination with SPIOs. However, due to the 
fact that cellular therapy in animal models and humans requires the administration of 
large cell numbers, the detection limit does not represent a problem within this 
context. The present study was actually carried out to establish a non-invasive 
modality for in vivo imaging of intraspinally injected hUCBCs in a transgenic ALS 
mouse model which mimics the human neurodegenerative disease in large parts. 
Nevertheless, the generated data can also be transferred to other settings such as 
cell-based cancer immunotherapeutic approaches, where in vivo monitoring of 
implanted cells is indispensable. In this context, tracking of SPIO-labelled DCs via 
MRI was reported to be realisable [226-231, 306-309], but there is more room for 
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further improvement due to the present availability of novel, more powerful magnetic 
iron oxide nanoparticles and MR scanners with increased field strengths.  
In conclusion, MRI as a clinical standard technique in combination with the 
commercially FDA-approved SPIO-contrast agent ENDOREM® provides valuable 
potential for non-toxic, non-invasive in vivo tracking of implanted cells in the murine 
model system. These data provide a basis to the future development of 
valuable in vivo cell monitoring tools for clinical trials assessing the benefit of cell 
transplantation human and veterinary medicine as well. 
In summary, within this thesis basic research on canine HMGB1, RAGE and 
associated cytokines revealed conserved molecular homologies and compareable 
expression patterns as seen in humans. This underlines the postulated high similarty 
of the involved tumour mechanisms allowing thereby a comparable prediction of 
responses to therapeutic agents in dogs and humans. In addition, the herein 
presented collaborative interdisciplinary work allowed the establishment of innovative 
methodical approaches contributing to the development of translational therapeutic 
strategies targeting at neoplasias in dogs as patients, whilst also offering benefit for 
human medicine.  
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5. Summary  
Cancer is a leading cause of death worldwide although extensive research in human 
cancer medicine is carried out. To develop and improve anticancer therapies, the 
mechanisms involved in the genesis and metastasis of tumours need to be 
elucidated. Herein, also the characterisation of the structure and function of cancer 
related genes and proteins is essential. In terms of cancer, the dog is one of the 
companion animals being considered as an invaluable model system in addition to 
the popular rodent model. Several canine neoplasias have been described to share 
striking similarities with humans and therefore are assumed to represent appropriate 
models for the corresponding human diseases. The spontaneous development of 
tumours in the context of an intact immune system in dogs offers new prospects for 
cancer immunotherapy in contrast to immunocompromised rodent models. Thus, 
basic research on tumour-associated genes provides valuable information for 
analysis of the comparative tumour biology between humans and dogs, and for the 
transferability of therapeutic approaches. 
Within this thesis, the molecular structure and function of the cancer-related genes 
and proteins HMGB1, RAGE, IL-1α, IL-1β, and TNF-α were analysed. The 
characterisation of human and canine RAGE splicing variants revealed highly 
conserved molecular similarities in both species. An expression analysis of HMGB1 
and RAGE in canine lymphoma showed similar expression patterns as observed in 
humans. An in silico analysis of the canine cytokines IL-1α, IL-1β, and TNF-α also 
identified conserved sequence homologies in comparison to other mammals.  
Besides basic research on cancer-related genes, parts of this thesis were conducted 
to support the development of a cell-based cancer immunotherapy vaccination 
strategy with genetically engineered recombinant HMGB1-secreting canine DCs in 
dogs. Within this project, opto-perforation using a femtosecond-laser for selective 
transfection was developed being also applicable for sensitive cell types. Additionally, 
another transfection method was established based on the application of a new type 
of laser-generated positively charged gold nanoparticles showing good efficiencies in 
a mammalian cell line. Furthermore, the functionality of different HMGB1 vectors and 
expression of the respective recombinant proteins were analysed. Subsequently, the 
time-dependent secretion of recombinant HMGB1 from generally HMGB1-non-
secreting mammary epithelial cells was induced by TNF-α stimulation. In the context 
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of cell stimulation, the potential of a CpG-ODN combined with IL-2 was investigated 
on canine B-cell lymphoma cells revealing an increased proliferative response.  
To monitor the fate of transplanted cells such as DC-vaccines non-invasively in vivo, 
more safely methods in comparison to the commonly used standard techniques are 
needed. Thus, the last part of this thesis presents the generation of antibody 
fragments targeting specifically canine DCs and improved cell tracking of 
SPIO-labelled cells via MRI, which can be used alternatively to follow cells in vivo.  
In summary, within this thesis the different fields of research allowed to establish 
innovative methods contributing to the development of therapeutic approaches 
targeting at neoplasias in dogs as patients, but also providing benefit for human 
medicine in terms of the dog as model organism.  
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6. Zusammenfassung  
Tumorerkrankungen sind weltweit eine der häufigsten Todesursachen. Daher wird 
intensive wissenschaftliche und klinische Forschung zur Entwicklung von Therapien 
betrieben. Um tumortherapeutische Ansätze entwickeln und verbessern zu können, 
müssen grundlegende Mechanismen aufgeklärt werden, die an der Entstehung und 
Metastasierung von Tumoren beteiligt sind. Hierbei spielt unter anderem die 
Charakterisierung der Struktur und Funktion von Genen sowie Proteinen eine 
wesentliche Rolle, die mit der Entstehung von Tumoren in Verbindung gebracht 
werden. Neben den klassischen Nagermodellen hat der Hund ein besonderes 
Interesse als Modelltier in der Humanmedizin erlangt, da viele canine Neoplasien 
auffallende Ähnlichkeiten zu denen des Menschen besitzen. Dabei bietet die 
spontane Entstehung von Tumoren in der Umgebung eines intakten Immunsystems 
bei Hunden neue Perspektiven für die Tumorimmuntherapie im Vergleich zu 
Nagermodellen, wobei vornehmlich immunsupprimierte Tiere verwendet werden. 
Somit liefert die Grundlagenforschung an tumorassoziierten Genen wertvolle 
Informationen zur Untersuchung der vergleichenden Tumorbiologie von Mensch und 
Hund und zur Übertragbarkeit von Therapieansätzen.  
Im Rahmen dieser Promotionsarbeit wurden die molekulare Struktur und Funktion 
der tumorassoziierten HMGB1, RAGE, IL-1α, IL-1β und TNF-α Gene und Proteine 
des Hundes analysiert. Die Charakterisierung von humanen und caninen RAGE 
Spleißvarianten zeigte hochkonservierte molekulare Homologien in beiden Spezies. 
Die Analyse der Expression von HMGB1 und RAGE in caninen Lymphomen ließ 
ähnliche Expressionsmuster wie beim Menschen erkennen. Weiterhin wurden in 
silico Analysen an den caninen Zytokinen IL-1α, IL-1β und TNF-α durchgeführt. Es 
zeigten sich hierbei stark konservierte Sequenzhomologien im Vergleich zu anderen 
Säugetieren.  
Neben der Erforschung grundlegender Genfunktionen trugen Teile dieser Arbeit zur 
Entwicklung einer genetisch modifizierten HMGB1-sezernierenden caninen 
DC-Vakzine zur Tumorimmuntherapie bei Hunden bei. Im Rahmen dieses Projektes 
wurde die neuartige Methode der Optoperforation mit einem Femtosekundenlaser zur 
selektiven Transfektion entwickelt, welche sich aufgrund der rein physikalischen 
Durchführung auch für sensitive Zelltypen eignet. Zusätzlich wurde ein weiteres 
Transfektionsverfahren etabliert, welches auf der Anwendung neuartiger 
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lasergenerierter Goldnanopartikel basiert und hohe Effizienzen in einer 
Säugerzelllinie zeigte. Weiterhin wurden die Funktionalität unterschiedlicher HMGB1-
Vektoren und die Expression der jeweiligen rekombinanten Proteine analysiert. 
Anschließend wurde die zeitabhängige Sezernierung von rekombinantem HMGB1 
aus einer caninen Mammaepithel-Zelllinie durch TNF-α Stimulation induziert. Ferner 
wurden canine primäre Lymphomzellen durch Applikation eines CpG-ODN in 
Kombination mit IL-2 zu einer erhöhten proliferativen Antwort angeregt.  
Um das Verbleiben von transplantierten Zellen wie z.B. DC-Vakzinen in vivo mit 
nicht-invasiven Methoden zu untersuchen, wird intensiv an sichereren und 
sensitiveren Nachweisverfahren gearbeitet. In diesem Zusammenhang wurde im 
letzten Teil dieser Arbeit an der Generierung hochspezifischer Antikörperfragmente 
zur Detektion von caninen DCs gearbeitet. Weiterhin wurde die in vivo 
Migrationsdetektion von SPIO-markierten Zellen mittels MRT verbessert.  
Die im Rahmen dieser Arbeit erzielten Ergebnisse tragen einerseits dazu bei, 
innovative Ansätze zur Tumortherapie bei Hunden in der Veterinärmedizin zu 
etablieren. Andererseits können die gewonnenen Erkenntnisse aufgrund der hohen 
Ähnlichkeit von Neoplasien bei Mensch und Hund einen wertvollen Beitrag zur 
Entwicklung vorklinischer Studien in der Humanmedizin liefern.   
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8. Abbreviations 
aa    Amino acid(s) 
Acc. No.  Accession number 
AGEs   Advanced glycation end products 
ALS    Amyotrophic lateral sclerosis 
AMD3100  CXCR4 antagonist; syn. Plerixafor 
APC   Antigen presenting cell 
AuNP   Gold nanoparticle 
bp    Base pair(s) 
BrdU   5-bromo-2-deoxyuridine 
CD    Cluster of differentiation 
cDNA   DNA complementary to RNA 
CDS   Coding sequence(s) 
CdSe    Ccadmium selenide 
CFA   Canis familiaris 
CGH    Comparative genomic hybridisation 
CHO cells  Chinese hamster ovary cells 
CLL   Chronic lymphatic leukaemia 
cm   Centimetre 
CNA   Copy number aberrations  
CpG Short single-stranded synthetic DNA molecules with 
cytosine-phosphodiester-guanine sequence motifs 
CRC    Collaborate research cluster 
C-terminal  Carboxy-terminal 
Cys   Cysteine  
CXCL12  Chemokine (C-X-C motif) ligand 12; syn. SDF-1 (stromal 
cell derived factor-1) 
DAB   3.3’-diaminobenzidine 
DAPI    4'-6-diamidino-2-phenylindole 
DC    Dendritic cell 
DFG Deutsche Forschungsgemeinschaft / German Research 
Foundation 
DNA    Deoxyribonucleic acid 
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DSP30  A specific CpG-ODN 
E. coli   Escherichia coli  
ED    Extracellular domain 
ELISA   Enzyme linked immunosorbent assay 
FA   Flip angle 
FCS   Fetal calf serum 
FDA   Food and Drug Administration 
FHD   FuGENE® HD; transfection reagent 
FoV   Field of view 
fs    Femtosecond 
G-CSF  Granulocyte colony-stimulating factor 
GFP   Green fluorescent protein 
EGFP   Enhanced green fluorescent protein 
hrGFP  Humanized renilla green fluorescent protein 
GUSB   Beta-glucuronidase 
h   Hours 
HMG    High mobility group 
HMGB1   High mobility group protein B1 
rHMGB1   Recombinant HMGB1 
eHMGB1  Endogenous HMGB1 
HRP   Horseradish peroxidase 
HSC   Haematopoietic stem cells 
hUCBCs  Human umbilical cord blood stem cells 
IFN-γ    Interferone gamma 
IgG   Immunoglobulin G 
IL   Interleukin 
IL-12   Interleukin-12 
IL-1α   Interleukin-1alpha 
IL-1β   Interleukin-1beta 
IL-2   Interleukin-2 
IL-6   Interleukin-6 
IRES    Internal ribosomal entry site 
kDa    Kilo Dalton 
Laser   Light Amplification by Stimulated Emission of Radiation 
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LPS   Lipopolysaccharides  
LZH   Laser Zentrum Hannover e.V.  
MAP kinase  Mitogen activated protein kinase 
MATra  Magnet-assisted transfection 
mg   Milligram 
MGE   Multi-gradient echo 
min   Minute 
MIP   Macrophage inflammatory protein 
ml   Millilitre 
µl   Microlitre 
µm   Micrometre 
mM   Millimolar 
MRI   Magnet resonance imaging 
mRNA   Messenger ribonucleic acid 
mW   Milliwatt 
NCBI    National Center for Biotechnology Information 
NFκB   Nuclear factor-kappa B 
ng   Nanogram 
NHL   Non-Hodgkin's lymphoma 
NIR   Near-infrared 
nJ   Nanojoule 
nm   Nanometre 
NMD   Nonsense-mediated decay 
NP   Nanoparticle  
N-terminal  Amino-terminal 
ODN   Oligodeoxynucleotides 
P   p-value 
PAGE   Polyacrylamide gel electrophoresis 
PBMC   Peripheral blood mononuclear cell 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PE   Phycoerythrin  
pEGFP-C1  Plasmid encoding enhanced green fluorescent protein 
pg   Picogram 
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PI   Propidium iodide 
PLAL   Pulsed laser ablation in liquids 
pRb   Retinoblastoma protein 
PVDF   Polyvinylidene difluorid 
QD   Quantum dots 
RAGE   Receptor for advanced glycation end products 
RNA   Ribonucleic acid 
RPM   Revolutions per minute 
scFV   Single-chain variable fragment 
SDS   Sodium dodecyl sulphate 
SNP   Single nucleotid polymorphism 
SOD1   Superoxide dismutase 1 
SPIO   Superparamagnetic iron oxide  
sRAGE  Soluble RAGE variant(s) 
T   Tesla 
TE   Echo time 
TLR   Toll-like receptor 
TMA   Tissue microarray 
TM   Transmembrane domain 
TNF-α   Tumour necrosis factor-alpha 
TR   Repetition time 
TR37    Transregio 37 
TREM-1  Rriggering receptor expressed on myeloid cells-1 
U   Unit 
UV   Ultraviolet 
WHO    World Health Organization 
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